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1. Summary 
 
The nerve growth factor family of neurotrophins consists of four well-studied 
members: Nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), 
neurotrophin 3 (NT-3) and neurotrophin 4 (NT-4). Neurotrophins are essential for the 
development, survival and maintenance of the nervous system. There is increasing 
evidence that neurotrophins and their receptors may have functions in the immune 
system. Nerve growth factor receptor (NGFR, p75NTR, TNFRSF16, CD271), encoded 
by NGFR gene, is the only receptor with the ability to signal in response to all 
neurotrophins. Although p75NTR has been intensively investigated under 
neurobiological aspects, little is known about its role in the immune system. 
The aim of this study was to quantify the expression of p75NTR in isolated 
populations of immune cells and in immune organs as well as to learn about its 
possible functions in the immune system using knockout mice. 
We identified, full-length transcripts of NGFR in human immune organs and in 
various immune cell subsets. In adenoids and tonsils NGFR gene was expressed 
comparable to CNS levels. Immunostaining with specific mAbs showed p75NTR on 
follicular dendritic cells and on a subset of germinal centre B cells. The study was 
further expanded to investigate human conditions that are known to be prone to 
formation of extranodal follicles. Expression of p75NTR in extranodal follicles of 
Hashimoto’s Thyroiditis (HT) and Follicular B cell Lymphoma suggests p75NTR 
mediated functions during  autoimmune diseases and malignancy. 
Conducting experiments on p75NTR exon 4 deficient animals was the final step 
of this project. Mice were immunized with three different antigens that served to 
induce germinal centre reaction, primary and memory response in terms of Ig 
production. Deletion of p75NTR did not cause any major alterations in immune cell 
compartments and memory response compared to wild type mice; on the other hand 
increased production of antigen specific IgM and elevated number of germinal 
centres in the spleen were observed in deficient animals. 
In conclusion the expression of p75NTR in normal lymphatic tissue suggests a 
role in the adaptive immune system. In vivo studies performed with p75NTR exon 4 
knockout mice indicate a modulatory role in selection, survival and maturation 
process of IgM memory B cells and/or IgM plasma cells. 
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2. Introduction 
 
The fate of cells is genetically programmed and under normal circumstances, 
each cell follows its program and performs the relevant function as much as the 
organism needs its contribution. In some special situations, strong effector signals 
coming from extracellular sources have the ability to initiate gene transcription to 
promote the cells to a much more capable state in many ways, as required by the 
organism. These factors and their respective receptors differ from each other among 
various cell types. Some of these proteins are secreted and can initiate target cells 
distributed in distant locations, while others need cell-to-cell interaction to exert their 
functions. Expression profiles of the receptors and ligands are determined by the 
actual status of the relevant tissue system. These factors may be referred as 
hormones, growth factors, trophic factors or cytokines depending on their target cell, 
the tissue they have been secreted or to the compartment where their functional 
characteristics were initially identified. As scientists go deeper in their investigations, 
growth factor families become much closer to each other, in some cases sharing 
receptors or ligands. 
In this context p75 neurotrophin receptor (p75NTR) could be a good example. It 
is a low affinity receptor that all members of the nerve growth factor (NGF) family of 
neurotrophins (NT) can signal through (Radeke et al., 1987; Rodriguez-Tebar et al., 
1992); structurally it is a member of tumour necrosis factor receptor superfamily 
(TNFRSF) (Hempstead and Chao 1989). Moreover, p75NTR has the ability to form 
receptor complexes with many different membrane proteins such as tropomyosin 
receptor kinase (Trk), Nogo and Sortilin receptors, leading to formation of high affinity 
targets for various ligands. There are many examples where a well-known growth 
factor turns out to be used or produced also by many other cell types. NGF itself can 
be considered a good example. It is synthesized in the hypothalamus, pituitary gland, 
thyroid gland, testes, and the epididymis, moreover various cell types including 
vascular smooth muscle cells, fibroblasts and some immune cells, also express it 
(Calzà et al., 1997). 
The vast majority of neuronal cell populations in the mammalian brain are 
formed prenatally, but still, some parts of the adult brain have the ability to 
regenerate by developing new neurons from neural stem cells. NTs are the key 
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factors that help to stimulate and control neurogenesis. Currently, in mammals, the 
NGF family of neurotrophic factors consist of four members: NGF (Levi-Montalcini, 
1987), BDNF (Brain derived neurotrophic factor) (Barde et al., 1982; Leibrock et al., 
1989), NT-3 (Neurotrophin 3) (Ernfors et al., 1990; Hohn et al., 1990; Maisonpierre et 
al., 1990, Rosenthal et al., 1990) and NT-4/5 (Neurotrophin 4/5) (Berkemeier et al., 
1991). NTs are synthesized as precursor proteins, then modified to mature forms and 
secreted. NTs form dimers to act through neurotrophin receptors. In the mature 
protein, half of the amino acid residues are common to all neurotrophins and they all 
share six cysteine residues at identical positions. This leads to the formation of the 
disulfide bridges and the similar tertiary structure of the molecules. The neurotrophins 
are able to form stable heterodimers in vitro (Jungbluth et al., 1994), but in vivo role 
of these NT heterodimers is not known. 
The NGF family of neurotrophins has been shown to modulate different 
functions in the nervous system. The main tasks of the NTs are: enhanced survival of 
neurons, development and maintenance of central and peripheral nervous system 
regulating the balanced release of neurotransmitters, dendrite growth and axonal 
regeneration after injury (Levi-Montalcini, 1987; Sendtner et al., 1992; Thoenen, 
1995; Lewin and Barde, 1996; Sawai et al., 1996; Barde, 1997; Semkova and 
Krieglstein, 1999). 
 
2.1 Neurotrophic factors 
2.1.1 Nerve growth factor (NGF) 
NGF is the member that the whole family was named after. It was identified 
more than a half century ago (Levi-Montalcini, 1952). The essential role of NGF is 
neuronal survival and development (Levi-Montalcini, 1987). NGF performs many 
other roles in the nervous system such as repair, regeneration, maintenance and 
protection of sympathetic and sensory neurons.  Mice lacking a functional NGF gene 
do not possess small diameter sensory neurons and sympathetic postganglionic 
neurons and die shortly after birth (Crowley et al., 1994). Newborn animals injected 
with anti-NGF antibodies, loose permanently the majority of sympathetic ganglion 
cells (Goedert et al., 1978). NGF is a 130-140-kDa complex composed of α, β and γ 
subunits (Bax et al., 1993). The biological activity is due to the β subunit (Fahnestock, 
1991); therefore the name βNGF is being used for this protein. Two β subunits 
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homodimerize to form the 26-kDa-polypeptide dimer (Ibanez, 1998; McDonald et al., 
1991). The βNGF gene is located on chromosome 1 in humans (Francke et al., 1983) 
and encodes a 34-kDa precursor also called pre-proNGF. An initial cleavage forms 
proNGF. A secondary enzymatic process by a furin or pro-convertase, leads to the 
formation of the mature and biologically active βNGF (Fahnestock, 1991; Chao, 
2003). Human and mouse proteins show 90% homology (Ullrich et al., 1983). 
NGF can signal through both TRKA and p75NTR that translate into activation of 
various signaling pathways depending on the TRKA-p75NTR ratio. 
 
2.1.2 Brain derived neurotrophic factor (BDNF) 
BDNF is the second member of the NGF family. As its name indicates, BDNF 
was originally found in brain tissue (Yves-Alain Barde, 1982). BDNF exerts its 
function mostly on certain neurons of the central nervous system (CNS) and 
peripheral nervous system (PNS). BDNF supports the survival of primary sensory 
neurons that are not responsive to NGF. BDNF has a trophic action on retinal, 
cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts 
on both motor and sensory neurons. BDNF does not only support existing neurons, 
but also promotes growth and differentiation of newly developing neurons through 
TrkB and p75NTR. 
The most obvious phenotype of BDNF knockout mouse is the lack of proper 
coordination of movement and balance. Morphologically, there is no reduction in size 
of cochlear ganglia, motor neurons of facial nucleus or lumbar spinal cord. On the 
contrary the volume of nodose-petrosal complex, vestibular and trigeminal ganglia 
were found to be reduced. Mice fail to thrive beyond postnatal day 8 and die around 3 
weeks of age. 
 
2.1.3 Neurotrophin 3 (NT-3) 
NT-3 was discovered due to its high resemblance to NGF and BDNF (Hohn et 
al., 1990) and it is encoded by Ntf3 gene. The obvious function of NT-3 is to support 
the survival and differentiation of existing neurons; additionally it promotes growth 
and differentiation of newly developing neurons and synapses. Activating TRKC, 
TRKB and p75NTR, NT-3 is considered special because it can potentially act on more 
target cells than any other NT. 
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The ligand dependent activation of TRKC by NT-3 prevents the myelination 
process. During the developmental phase of glial proliferation and elongation, NT-3 
levels decrease whereas TRKC and p75NTR remain constant. With the initiation of 
myelination, NT-3 protein levels drop to undetectable amounts, stopping the 
inhibitory action (Cosgaya et al., 2002). 
Ntf3 deficient mice showed severe movement defects of the limbs, and the 
majority died shortly after birth (Ernfors et al., 1994). It was observed that 
considerable portions of peripheral sensory and sympathetic neurons were lost, 
whereas motor neurons were not affected. A quantitative analysis revealed that the 
number of muscle spindles in heterozygous mice was half of that of control mice. 
When NT-3 was inactivated in embryonic stem cells (ESC), homozygous knockouts 
completely lacked peripheral sense (Tessarollo et al., 1994). In the same model, 
knockout animals exhibited severe neurological dysfunction. A loss of muscle 
sensory neurons has been observed in targeted mutation of Ntf3 in mouse (Klein et 
al., 1994). Additionally, perinatal death seen in Ntf3 deficient mice is presumably due 
to the essential role of NT-3 in heart development (Donovan et al., 1996). 
 
2.1.4 Neurotrophin 4 (NT-4) 
NT-4 has not been as extensively studied as the rest of the family. It is 
encoded by Ntf4 gene. There are several points about NT-4 that make this 
neurotrophin look different than others. NT-4 expression is ubiquitous and its 
modulation seems to be independent from environmental factors (Ip et al., 1992), but 
dependent on p75NTR for competent signaling (Rydén et al., 1995), as well as 
neuronal retrograde transport (Curtis et al., 1995). 
Ntf4 deficient mice examined so far have only minor cellular deficits (loss of 
sensory neurons in the nodose-petrosal and geniculate ganglia) and develop 
normally after birth (Conover et al., 1995; Liu et al., 1995). A detailed examination of 
the learning and memory functions of Ntf4 deficient mice with the use of fear 
conditioning, revealed significant deficits in mutant animals at 2 and 24 hours after 
training, on the other hand the result for 30 minutes was similar. Experiments on 
slices prepared from hippocampus revealed a decrease in long-term potentiation (Xie 
et al., 2000). NT-4 can signal through both TRKB and p75NTR. 
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2.1.5 Pro-Neurotrophins 
Members of the NGF family of neurotrophins are processed intracellularly from 
immature precursors called proneurotrophins (ProNT). At the initial phase ProNTs 
have been considered inactive precursors. Further investigation in recent years 
demonstrated that this is not the exact situation. ProNGF has been identified as the 
predominant form of NGF in many tissues and it turned out to be a biologically 
important molecule (Lee et al., 2001; Fahnestock et al., 2001; Pedraza et al., 2005; 
and Reinshagen et al., 2000). 
ProNGF and proBDNF were shown to be cleaved extracellularly, following 
their secretion. The process is performed by numerous proteolytic enzymes including 
furin, plasmin and MMPs (Lee et al., 2001). 
ProNGF is the best-studied pro-neurotrophin. It is the high-affinity ligand for 
p75NTR-Sortilin receptor complex and it induces apoptosis in neurons (Nykjaer et al., 
2004). Moreover, proNGF mediates cell death of oligodendrocytes following spinal 
cord injury in vivo (Beattie et al., 2002). Additionally, proNGF has been suggested to 
be responsible for the neurodegeneration that occurs in the brains of Alzheimer’s 
disease patients (Pedraza et al., 2005). These new findings have brought an 
increased complexity to the NT research. 
 
2.2 Neurotrophic factor receptors 
P75NTR and Trk receptor family are the two types of receptors responsible for 
transducing neurotrophin signals. They have different structural components to 
activate downstream signaling pathways. P75NTR and Trk receptors were 
denominated as low- and high-affinity receptors as they have dissociation constants 
of 10−9 M and 10−11 M respectively for mature NGF (Lewin and Barde, 1996; 
Friedman and Greene, 1999). Recent studies on “so called” low-affinity receptor 
p75NTR and high affinity Trk receptors revealed that the presence of both type 
receptors is required on the same cell for establishment of real high affinity sites for 
the neurotrophins (Hempstead et al., 1991, Bibel et al., 1999, Roux and Barker, 
2002). As a pan-neurotrophin receptor, p75NTR can be triggered by all members of 
the NGF family (Rodríguez-Tebar et al., 1990, 1992; Hempstead, 2002). On the other 
hand, each Trk receptor has a preferential ligand that binds with higher affinity. 
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Another crucial difference between these two receptor types is the lack of a catalytic 
tyrosine kinase domain in p75NTR. 
 
2.2.1 P75NTR the orphan TNF receptor 
The p75NTR is the first receptor that has been identified as NGF receptor. It is a 
75-kDa glycoprotein (Huebner et al., 1986) and has four cysteine-rich regions (CRR) 
in the extra cellular domain (ECD). P75NTR belongs to the family of TNF receptors, 
which contains many receptors as CD40, OX-40, FAS and BAFF-R that are all 
indispensable for immune system functions. This family of receptors is mainly 
distinguished with their multiple CRRs for ligand binding, a single pass 
transmembrane domain and a non-catalytic cytoplasmic domain (Locksley et al., 
2003). Although being a member of TNFR superfamily, a TNF ligand for p75NTR has 
not been identified so far. The sequences of four CRRs are responsible for the 
negatively charged structure and for binding of all neurotrophins of the NGF family to 
the receptor (Chapman and Kuntz, 1995), with similar affinities (Rodríguez-Tebar et 
al., 1990, 1992; Hempstead, 2002). 
P75NTR protein has three major domains that interact with ligands, co-
receptors or adapter proteins: Neurotrophin binding domain, intracellular juxta-
membrane domain and death domain. The neurotrophin-binding domain is 
composed of three cysteine rich regions coded by exon 3. Both intracellular juxta-
membrane domains coded by exon 5 and death domain coded by exon 6 play 
important roles to substitute for the lack of a catalytic domain. They provide binding 
sites for recruiting adapter proteins required for downstream signaling. There is only 
one transcript variant reported so far, which lacks exon 3, coding for the neurotrophin 
binding domain. This short isoform is not able to bind to neurotrophins but can 
interact with Trk receptors. It is called s-p75 and had only been reported to exist in 
mice (von Schack et al., 2001, Ibanez, 2002). Neurotrophins and Trk receptors 
always form dimeric molecules whereas p75NTR can form dimers as well as trimers 
similar to other members of the TNF receptor superfamily (Anastasia et al., 2015). 
ProNGF binds to p75NTR with high affinity and induces apoptosis (Lee et al., 
2001, Beattie et al., 2002). A 95-kDa co-receptor called Sortilin (encoded by SORT1 
gene) is required for induction of apoptosis by formation of a high affinity receptor 
complex with p75NTR (Nykjaer et al., 2004). This apoptotic effect mediated by the 
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p75NTR – Sortilin complex and proNGF is not unique; proBDNF leads to similar 
consequences (Teng et al., 2005). Additional to p75NTR - Trk and NT-proNT ratios, 
the presence or absence of sortilin on the same cell that expresses p75NTR will also 
determine cell fate. In fact, the inhibition of sortilin, specifically in p75NTR expressing 
neurons, suppresses proNT mediated apoptotic action (Lu et al., 2005).  
Activation of the p75NTR by NTs and proNTs induces recruitment of several 
adapter proteins that promote cell survival as well as apoptosis (Hempstead and 
Salzer, 2002), these adapter proteins are widely shared among other members of 
TNFR superfamily. TRAF6, NRIF, NRAGE, NADE, IRAK and SC-1 have been 
identified as adapter proteins interacting with intracellular domains of p75NTR (Fig. 
2.2, reviewed by Arévalo and Wu 2006). 
 
Figure 2.2 
Overview of neurotrophin or pro-neurotrophin mediated signaling through p75NTR. Many adapter 
proteins can be recruited to the p75 intracellular domain. TRAF6, NRIF, NRAGE, NADE, IRAK and 
SC-1 can interact with p75-ICD. Initiation of various pathways through different adapter molecules 
results in a range of effects including axonal growth, growth cone collapse, survival, and apoptosis or 
cell cycle arrest. Trk receptor signaling may block cell death signaling through p75NTR. Modified from 
Arévalo and Wu 2006. 
 
Introduction 9 
TNF ligands and receptors are processed by proteases, yielding soluble effector 
proteins or intracellular signaling elements. As being a member of TNFR superfamily, 
p75NTR carries a similar feature. A ligand independent α-secretase cleavage of 
p75NTR leads to a soluble p75 fraction called p75ECD (extracellular domain) and a 
membrane bound fraction called p75ICD (intracellular domain) (DiStefano and 
Johnson, 1988; Zupan et al., 1989; Barker et al., 1991; DiStefano et al., 1993). 
Accumulation of p75ICD promotes cell death. A consecutive γ-secretase cleavage of 
p75ICD yields an intracellular fragment with nuclear functions (Kanning et al., 2003). 
α-secretase or γ-secretase cleavage of p75NTR activates different intracellular 
signaling pathways (Vicario et al., 2015). The α-secretase enzyme cleaving p75NTR is 
called TACE (Tumour necrosis factor α converting enzyme). There are a number of 
studies reporting that interaction of p75NTR with other proteins like sortilin (Skjeldal et 
al., 2012), Trk receptors (Ceni et al., 2010) and myelin associated ligands 
(Domeniconi et al., 2005) influence its proteolytic cleavage. Recent research showed 
that the ectodomain of p75NTR has neuroprotective role against amyloid-beta plaque 
toxicity during Alzheimer’s disease (Yao X-Q et al., 2015). 
Modulation of axonal growth depends on different ligands and adapter 
proteins that interact with p75NTR. While neurotrophin signaling promotes axonal 
growth, myelin-derived growth inhibitors lead to growth cone collapse. Neurotrophins 
have also roles on regulation of RhoA, which has the ability to manage the 
organization of the actin cytoskeleton in many cell types (Jaffe and Hall, 2005). 
Tuning of the axonal growth through p75NTR-RhoA pathway is not restricted to 
neurotrophins. A triple receptor complex formed by p75NTR, sortilin and NGR (Nogo 
receptor, encoded by RTN4R gene) is also responsible for mediating inhibitory 
signals for axonal outgrowth. Identified ligands for this complex are myelin-associated 
glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (OMgp) (Wang et al., 
2002; Wong et al., 2002; Mi et al., 2004). It has also been shown that functional 
LINGO1-p75NTR-NGR complexes formed in the plasma membrane and LINGO1 
interacts with intracellular membrane compartments of p75NTR (Meabon et al., 2015). 
Recently, several studies linked p75NTR expression to cancer stem cells (Dirks 
F. 2010). It was reported that NGF/proNGF/p75NTR signaling plays a critical role in 
cancer stem cell self-renewal and plasticity regulation in breast cancer (Tomellini et 
al., 2015) and melanoma-initiating cells express p75NTR (Boiko et al., 2010). 
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Moreover, p75NTR is shown to be a marker for tumor-initiating cells in squamous cell 
carcinoma (Murillo-Sauca 2014). 
There is a wide range of functions that have been associated to p75NTR, but 
the complete signaling pathways and complexity of the involving adapter proteins 
stand as difficult task to solve for the scientists. 
P75NTR proves itself to be a unique receptor in many ways:  
• Although being a member of the TNFR superfamily, there is no TNF ligand 
associated with p75NTR yet. 
• P75NTR can signal in the presence of all four known neurotrophins. 
• P75NTR and sortilin form a high affinity receptor complex for proNTs. 
• P75NTR undergoes α− and γ-secretase mediated shedding, resulting in 
bioactive intracellular fragments. 
• P75NTR forms a receptor complex with NGR and LINGO1 for myelin-derived 
growth inhibitors like myelin-associated glycoprotein (MAG), and 
oligodendrocyte myelin glycoprotein (OMgp). 
• P75NTR is a stem cell marker for a variety of cancers. 
• Diversity in functions: 
- Promote survival – Induce apoptosis 
- Neurite outgrow – Growth cone collapse 
- Mediate differentiation 
- Enhance proliferation 
- Facilitate myelination 
(Cosgaya et al., 2002, Yamauchi et al., 2004, Du et al., 2006) 
 
2.2.2 Trk family of neurotrophin receptors 
The protein tyrosine kinase Trk receptors TRKA, TRKB and TRKC act as 
specific, high-affinity neurotrophin receptors. Each of the Trk family members shows 
a preferential ligand binding ability to NTs (Ip et al., 1993). TRKA is the preferred 
receptor for NGF (Kaplan et al., 1991; Klein et al., 1991), but has a lower affinity for 
NT-3 or NT4/5. Both BDNF and NT-4 can bind to TRKB. TRKC has a unique ligand, 
NT-3 (Lamballe et al., 1991), but on the other hand NT-3 can also bind to TRKB with 
a low affinity (Klein et al., 1991; Ip et al., 1992) (Fig. 2.1). 
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Figure 2.1 
Overview of Trk receptors and their preferential neurotrophin ligands. 
Trk receptors have three leucine-rich regions (LRR) and two Ig like domains mapped in the 
extracellular part. The tyrosine kinase domain is located in the intracellular section. Trk Family 
members share around 50% of their amino acid sequence. NGF selectively binds to TrkA, BDNF and 
NT-4 to TrkB, finally NT-3 to TrkC. Modified from Arévalo and Wu 2006. 
 
All three Trk receptors harbour a cytosolic domain whose tyrosine-kinase 
activity is essential for the signal transduction. On the extracellular part they carry 
three leucine rich regions (LRR) and two Ig like C2 type domains (Ig-C2). They have 
a single pass trans-membrane domain coupled with a kinase domain. Neurotrophin 
binding occurs through the Ig-C2 domains (Perez et al., 1995). In situations when 
there is no interaction with a neurotrophin, the Ig-C2 domains prevent dimerization of 
the Trk receptors and auto-phosphorylation of the tyrosine kinases (Arevalo et al., 
2000). Trk receptors carry structural similarities to each other; they have around 50% 
amino acid homology. 
The main components of Trk receptor downstream signaling pathway are 
phospholipase C-gamma (PLC-γ), phosphodityl-insitol 3-kinase (PI3-kinase) and 
SHC adapter proteins. PLC-γ catalyzes the hydrolysis of membrane phospholipids to 
generate inositol triphosphate (IP3), which is responsible of activating pathways to 
induce changes in intracellular Ca2+, pH, cytoskeletal functions and gene 
transcription. PI3-kinase produces phosphoinositides that activate AKT protein 
kinase, which results in growth factor mediated cell survival. SHC adapter proteins, 
when phosphorylated by tyrosine kinases, activate RAS and MAP-kinase pathways 
that in turn activate nuclear transcription factors. 
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2.2.2.a TRKA 
The TrkA receptor is encoded by NTRK1 gene located on chromosome 1 
(Martin-Zanca et al., 1986). It is a 140-kDa trans-membrane protein possessing a 
tyrosine-kinase domain in the intracellular part. Another key domain of TRKA is the 
NT binding domain that harbors two Ig-like domains that are involved in NGF 
selectivity and binding (Wiesmann et al., 1999). The expression profile of the TRKA 
receptor is widely spread throughout the nervous system (Muragaki et al., 1995). 
Receptor homo-dimerization is required for tyrosine kinase activation; this 
occurs when NGF binds to the receptor, initiating transphosphorylation (Kaplan et al., 
1991). This activation involves a group of proteins playing key roles for the cellular 
functions:  RAS, phospholipase C (PLC), protein kinases C (PKC) and phosphatidyl-
inositol-3 kinase (PI3) (Obermeier et al., 1993a,b; Melamed et al., 1999; York et al., 
2000). The mitogen-activated protein kinase (MAPK) pathways are activated next 
(Kaplan and Miller, 1997). NGF activation of the TrkA receptor inhibits apoptosis and 
induces cell proliferation, differentiation and survival (Levi-Montalcini, 1987; Levi 
Montalcini et al., 1995; Aloe et al., 1997; Bonini et al., 2002). 
 
2.2.2.b TRKB 
Identification of TRKB was based on its similarity to TRKA. Human TRKB is 
encoded by NTRK2 gene that consists of 24 exons (Yeo et al., 2004). TRKB protein 
is a single pass transmembrane protein of 822 amino acid residues and the peptide 
sequence is found to be 49% homologue to TRKA and 55% to TRKC.  TRKB is 
known as high affinity receptor for BDNF and both together they regulate short-term 
synaptic functions and long-term potentiation of brain synapses. There are three 
TRKB isoforms in mammals. The full-length TRKB has the typical tyrosine kinase 
activity, which can transduce BDNF and NT-3 signals to a lesser degree. The two 
other truncated isoforms are sharing the same extracellular and trans-membrane 
domains but showing differences in the intracellular part. These isoforms are named 
as TK-T1 and TK-T2. Additional to splice isoforms, there are also TRKB extracellular 
deletions, leading decreased responsiveness to BDNF and restriction of NT-3 and 
NT-4 activation (Kristen et al., 1999). 
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The first generation of a Ntrk2 deficient mouse allowed scientists to observe 
neuronal deficiencies in central and peripheral nervous systems (Klein et al., 1993). 
Observations were limited to prenatal period and postnatal day 1, which is the point 
the animals die. Although this knockout served well for understanding the TRKB 
receptor functions, its impact during postnatal neuronal development was still an 
open question. The Cre-loxP recombination technique has been used to generate 
animals that lack TRKB expression in the forebrain (Minichiello et al., 1999). These 
mice were viable and did not show major morphologic alterations.  They were, 
however, highly impaired in learning under stress conditions (Minichiello et al., 1999). 
In following years, animal models with disrupted phospholipase C docking site or 
SHC domain helped better understanding the TRKB functions. PLCγ disruption 
caused weakened hippocampal long-term potentiation (LTP). In case of SHC 
disruption, the process had no effect on LTP, but a reduction of MAPK activation was 
observed on those neurons that had been stimulated with BDNF (Minichiello et al., 
2002). 
 
2.2.2.c TRKC 
TRKC is coded by NTRK3 gene and it is the third member of the Trk family is 
preferentially expressed in the brain (Lamballe et al., 1991), mRNA specific 
hybridisation showed distributed expression in the hippocampus, cerebral cortex, and 
the granular cell layer of the cerebellum. TRKC protein has a molecular weigh of 145-
kDa. TRKC is the high affinity receptor for NT-3 and does not engage with NGF or 
BDNF. 
Schwann cell function during the development and regeneration of the 
peripheral nervous system is highly dependent on neurotrophic factor signaling. 
Although neurotrophins are known to be the key mediators for myelination, 
abundance of various neurotrophins and the distribution of neurotrophin receptors 
are crucial for proper myelination. In this context TRKC-NT3 signaling has rather an 
inhibitory effect whereas p75NTR-BDNF enhances myelination (Cosgaya et al., 2002). 
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2.3 Ngfr knockout mice 
Two different knockout mouse models for p75NTR have been developed so far. 
The first model is generated by deletion of exon 3 of Ngfr, coding for the three 
cystein-rich regions forming the neurotrophin-binding domain (Lee et al., 1992). The 
exon 3 knockout mice still express a p75 protein variant (s-p75) consisting of one 
cysteine-rich domain, stalk domain, transmembrane domain and intracellular domain. 
Intensive PCR analysis performed on human, mouse, rat and chicken revealed that 
s-p75 is conserved across species. Primary Schwann cells obtained from p75NTR 
exon 3 knockout mice still express the s-p75 variant that cannot bind neurotrophins 
but interacts with Trk receptors (von Schack et al., 2001). 
Another p75NTR knockout mouse has been generated by targeting exon 4, 
therefore it lacks the transmembrane domain (von Schack et al., 2001). In 2004, Paul 
et al. reported that a functional fragment of p75NTR is still produced in exon 4 
knockout mice. When overexpressed, this fragment associates with the membrane 
and it is able to trigger an apoptotic signal (Paul et al., 2004). Both p75NTR exon 3 and 
exon 4 knockout mice are suitable to investigate NT dependent functions of p75NTR 
but there is still a need for a knockout model for the investigation of NT independent 
functions. 
 
2.3.1. P75NTR exon 3 knockout mouse 
P75NTR exon 3 KO mice (Lee et al., 1992) are viable but smaller than wild-type 
littermates. Increased skin infections, loss of nails and hair follicles at distal 
extremities have been observed as major phenotype. KO mice lack 50% of sensory 
neurons that require more NGF for survival due to 2-3 fold decreased sensitivity to 
NGF. Loss of sensory neurons mainly translated to a decreased innervation of the 
skin. Similarly, impaired heat sensitivity is consistent with decreased cutaneous 
innervation. Further defects include lack of 40% of dorsal root ganglia (DRG) neurons 
and Schwann cells; the cross-section of the sciatic nerve is 40% smaller.  
 
2.3.2. P75NTR exon 4 knockout mouse 
P75NTR exon 4 KO mice (von Schack et al., 2001) were generated after the 
discovery of s-p75, in order to achieve a complete knockout model. In general exon 4 
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KO mice show a more drastic phenotype compared to exon 3 KO mice. They are 
much smaller than WT mice especially during postnatal period. About 40% do not 
survive beyond the prenatal period. Most of blood vessels have thin walls and leak 
blood. The exon 4 KO mice lack 54% of DRG neurons and 61% of the Schwann 
cells. The cross-section of the sciatic nerve is significantly (54%) smaller compared to 
WT. 
 
2.4 Neurotrophic factors and the immune system 
In parallel to the identification of the complete family of neurotrophins and 
receptors, an intense scientific work was allocated to solve the functional puzzle of 
this growth factor family and their receptors. Secreted neurotrophins also play 
important roles during sympathetic innervation. In this context NGF is shown to take 
part in the innervation of the lymphoid organs (Kannan et al., 1994, 1996). Cells 
expressing NTs and NTRs were partially mapped. In the immune system NTs and 
NTRs were prominently expressed in some cell subsets of primary and secondary 
lymphoid organs (Morgan et. al., 1989; Ciriaco et al., 1996; Aloe et al., 1999; 
Hannestad et al., 1995, 1997). 
 
2.4.1 NGF 
NGF is constitutively expressed in the thymus; mostly in the medulla (Katoh-
Semba et al., 1993; Aloe et al., 1997; Turrini et al., 2001) and a role for NGF through 
p75NTR and TrkA during the T cell development in the thymus has been suggested 
(Marinova et al., 2003). NGF increased the transcription of IL-6 in thymic epithelial 
cells (Screpanti et al., 1992). 
Mast cells (Leon et al., 1994) and T cells have been shown to produce NGF 
(Ehrhard et al., 1993; Santambrogio et al., 1994; Lambiase et al., 1997), but the level 
of NGF expression is highly dependent on T cell activation (Ehrhard et al., 1993, 
Moalem et al., 2000). Both CD4+ and CD8+ populations produce NGF. The level of 
NGF expression is reported to increase following antigen stimulation, especially in 
the Th2 subset (Santambrogio et al., 1994, Van Eden et al., 2002). 
NGF has also ability to increase survival of memory B cells (Rubartelli et al., 
1996) and has been reported to rescue B cells from experimentally induced 
apoptosis (Kronfeld et al., 2002, Torcia et al., 1996 and 2001). Similarly, NGF 
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increases survival of macrophages (Garaci et al., 1999) and monocytes (la Sala et 
al., 2000). Moreover, NGF has been shown to synergetically act with granulocyte-
macrophage colony stimulating factor (GM-CSF) to promote human basophilic cell 
differentiation (Tsuda et al 1991) and to support hemopoietic stem cell development 
(Chevalier et al., 1994, Auffray et al., 1996). In the mouse, NGF acted as a 
chemotactic agent on macrophages (Kobayashi et al., 2001) and mast cells (Sawada 
et al., 2000) 
NGF has been considered as a potential biomarker following several studies 
that were performed in this context. An increased serum level of NGF is found to be 
quite common during allergic diseases (Frossard et al., 2004), autoimmune disorders 
(Aloe and Tuveri. 1997, Arredondo et al., 2001), other inflammatory cases (Stanisz 
M. and Stanisz J. 2000) and stress (Aloe et al., 1994). 
Another cell type that is responsive to NGF are bone marrow stromal cells 
(Rezaee et al., 2010). It is reported that they increase IL-6 expression by activation of 
ERK and p38 MAPK, but not NFκB. 
Recently, it has been shown that NGF attenuates the inflammatory response 
in LPS activated monocytes by inhibiting production of proinflammatory cytokines, 
including IL-1β, IL-6, and TNF-α and by inducing IL-10 and IL-1Ra through TRKA 
receptor (Prencipe et al., 2014).  
 
2.4.2 BDNF 
Within the immune system, the presence of BDNF has been first shown in the 
thymus (Laurenzi et al., 1994; Yamamoto et al., 1996; Timmusk et al., 1999). The 
main source of BDNF was found to be the stromal cells (Maroder et al., 1996). TrkB 
receptor expression was reported on immature thymocytes (Maroder et al., 1996). 
Both CD4+ and CD8+ T cells were reported to transcribe BDNF mRNA and to 
produce biologically active BDNF (Braun et al., 1999; Kerschensteiner et al., 1999). 
BDNF was reported to modulate cytokine expression of PBMCs through Trk 
receptors. Additionally antigen specific T cells had a change in the expression pattern 
of IL-4, TGFβ, TNFα and INFβ (Bayas et al., 2003). 
Recently, a developmental block in the Pre-BII stage in B cells has been 
reported in BDNF knockout mouse (Schuhmann et al., 2005), leading to significant 
reduction of the B cells in the bone marrow, spleen and blood. 
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Moreover, BDNF have found to be produced and used by thymic epithelial 
cells (TEC) and immune cells in the thymus (Berzi et al., 2008), suggesting a role for 
T cell proliferation and TEC turnover. 
 
2.4.3 NT-3 and NT-4 
Compared NGF and BDNF, NT-3 and NT-4 were not as deeply investigated in 
the immune system. Both NT-3 and NT-4 were reported to exist at both mRNA and 
protein level in the thymus (Laurenzi et al., 1994, Timmusk et al., 1993, Katoh-
Semba et al., 1996). Additionally, NT-3 protein has been detected in the spleen 
(Zhou & Rush, 1993; Katoh-Semba et al., 1996). NTF3 and NTF4 transcripts were 
reported in CD4+ and CD8+ T cells (Moalem et al., 2000). At protein level, B cells 
were shown to produce NT-3 (Besser and Wank, 1999). 
 
2.4.4 P75NTR 
As being able to conduct signals in the presence of all of the NTs and pro-
NTs, p75NTR can be considered as an important marker for cells that could respond to 
NTs. In the thymus, p75NTR was found to be expressed by dendritic cells (Parrens et 
al., 1999; García-Suárez et al., 2001) and by medullary epithelial cells (Lomen-
Hoerth & Shooter, 1995).  
The spleen shows a rather compartmentalized expression of p75NTR in follicles 
(Labouyrie et al., 1997). In human tonsils and adenoids, p75NTR is also present in 
lymphoid follicles, mainly expressed by follicular dendritic cells (FDC) and 
lymphocytes (Chesa et al., 1988; Brodie and Gelfand, 1992; Pezzati et al., 1992). 
Additionally, periarteriolar macrophages and dendritic cells are reported to be positive 
for p75NTR (Pezzati et al., 1992; Bull et al., 1998; García-Suárez et al., 1997; 
Labouyrie et al., 1997). P75NTR expression was also located in blood vessels, in the 
Schwann cells of nerve endings and in the basal epithelium of the mucosa (Esteban 
et. al. 1995). 
The expression of p75NTR by T cells (Kittur et al., 1992; Ehrhard et al., 1993) 
and by B cells is controversial (Brodie et al., 1996, Schenone et al., 1996).  The 
expression pattern for the T cell and B cell lineages under different activation 
conditions has never been completely elaborated. There are many conflicting reports 
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about the expression of NTs and NTRs, mainly due to the variations between 
targeted cell population and their stage of activation or maturation.  
In 2008, Berzi and colleagues revealed that p75NTR is expressed by thymic B 
cells and thymic epithelial cells (TEC) in healthy adult human thymus. In the same 
study, p75NTR and BDNF were reported to be colocalized on the proliferating B cells 
in the germinal centre of the hyperplastic thymus. 
Recently it has been reported that plasmocytoid dendritic cells express p75NTR 
but not Trk receptors (Bandola et al., 2017) and demonstrated p75NTR - NGF driven 
regulation of T cell priming and cytokine production. 
 
2.4.5 Trk Receptors 
Trk receptors were discovered shortly after p75NTR and this finding initiated a 
massive research concerning their functions in different organ systems. The 
discovery of the thymus specific splice variants of TrkA (Dubus et al., 2000) 
strengthened the idea of NTs having broader functions in the thymus.  
Transcripts of full-length (Laurenzi et al., 1994; García-Suárez et al., 2002) 
and truncated isoforms of Ntrk2 have been reported in the thymus (Lomen-Hoerth & 
Shooter, 1995). TRKB protein been detected in thymocytes (Maroder et al., 1996; 
Besser & Wank, 1999; García- Suárez et al., 2002), in stromal cells and in 
macrophages (García-Suárez et al., 1998, 2002, Levanti et al., 2001, Rezaee et al., 
2010). On the other hand, protein expression of TRKC has never been reported. 
In the human spleen, TRKA and TRKB were reported to be expressed, mainly 
by the FDCs (Labouyrie et al., 1997). TRKB was also detected in the splenic 
macrophages (Shibayama & Koizumi, 1996). 
In peripheral blood, mainly T cell populations express TRKB, both isoforms 
have been detected on CD4+ T cells (Besser & Wank, 1999) and CD3+ T cells (Berzi 
et al., 2008). Similar to the NT production, TRKB expression level depends on the 
different developmental stages of T cell populations (Maroder et al., 1996, 2000). 
TrkA expression in B cells is controversial, it has been reported to exist in B cells 
(Melamed et al., 1996; Torcia et al., 1996; D’Onofrio et al., 2000), but on the other 
hand Schenone et al., (1996) stated that neither mRNA, nor protein for TRKA exists 
in B cells. Recent studies confirm the TRKB expression on B cells (Besser & Wank 
1999, D’Onofrio et al., 2000, Berzi et al., 2008). TRKA has been detected on 
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monocytes and LPS activation induces its expression (Ehrhard et al., 1993a, 1993b; 
Prencipe et al., 2014). On the other hand, TRKA expression is found to be down 
regulated during differentiation to macrophages in-vitro (Ehrhard et al., 1993). 
In summary, the NGF-TRKA pair, as being the most studied receptor-ligand 
pair, might function in the immune system. Although there are examples of functions 
concerning both T and B cell biology, each different immune subset seems to bear a 
unique set of NTs and their receptors. 
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3. Objectives 
 
This study was undertaken with the following objectives. 
 
1. To identify immune cell subsets expressing p75NTR in blood and immune 
organs and to determine whether p75NTR expression changes in response to 
immune cell activation/maturation. 
 
2. To investigate p75NTR in follicular B cell lymphoma and in extranodal 
lymphoid follicles occurring in autoimmune Hashimoto’s Thyroiditis. 
 
3. To learn about a possible role of p75NTR in the regulation of humoral 
immunity by studying p75NTR exon 4 knockout mice. 
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4. Material and Methods 
 
4.1 Materials 
4.1.1 Buffers and reagents 
a. Main buffers 
Phosphate buffered saline (1X PBS), pH 7.4  
9.1 mM Na2HPO4 
1.7 mM NaH2PO4  
150 mM NaCl 
 
Tris buffered saline (1X TBS) 
10 mM Tris-HCl, pH 8.0 
150 mM NaCl 
 
b. ELISA buffers 
ELISA coating buffer, pH 9.6 
15 mM Na2CO3  
35 mM NaHCO3 
 
ELISA washing buffer  
1X PBS + 0.05% Tween-20 
 
ELISA blocking buffer 
1X PBS + 2-10% FCS 
 
ELISA substrate buffers 
1- 20 mM Na2HPO4 +10 mM C6H8O7 (Cirtic acid)  
Immediately before use, add 1/1000 v/v 3% H2O2 and 1-2 g OPD  
(O-Phenylenediamine), pH 4 – 4,5. Read at 492 nm 
2- TMB (Tetra-methyl-benzidine) substrate solution (Sigma) 
Filters: Read 450 nm, reference 550 nm 
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ELISA stop solution 
1 or 2 M H2SO4 
 
c. RNA-DNA-PCR buffers 
TAE Buffer (Tris-Acetate-EDTA) 50x 
242 g Tris base 
57.1 ml Acetic acid 
100 ml 0.5 M EDTA 
 Add distilled water to 1 liter and adjust pH to 8.5 
 
Lysis Buffer: RNA extraction from FFPE tissue 
1 M Tris-HCl 
0.5 M EDTA 
10% SDS 
pH 8 
Add 20 mg/ml Proteinase K (Sigma), (Add fresh before use)  
 
Tail digestion buffer 
100 mM Tris-HCl, pH 8.5 
200 mM NaCl 
5 mM EDTA 
0.2% SDS 
100 µg/ml Proteinase K (Sigma), (Add fresh before use) 
 
d. FACS buffers/reagents 
FACS buffer (staining/washing) 
1X PBS + 2% heat-inactivated FCS 
 
Cell permeabilization buffer 
1X PBS + 1% heat-inactivated FCS + 0.1% (w/v) saponin (Sigma), pH 7.4 
 
Propidium Iodide solution 
1 mg/ml in 1X PBS 
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e. Immuno-staining buffers 
Cell/Tissue section fixing solution - 4% PFA  
Paraformaldehyde 4% (w/v) in 1X PBS, pH 7.4 
 
Endogenous peroxidase activity stopping solution 
3% H2O2 in methanol 
 
Blocking buffer 
1X PBS + 10% heat-inactivated FCS + 5% serum from secondary antibody host 
animal. 
 
f. Cell culture reagents 
Cell culture medium 
RPMI 1640 (Gibco) 
1% Pen-strep (Penicillin G 10,000 units/ml; streptomycin 10,000 µg/ml; Gibco) 
5% or 10% heat-inactivated fetal calf serum (FCS) 
 
Red blood cells (RBC) lysis buffer 
0.83% ammonium chloride in PBS or RBC lysis solution (Qiagen) 
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4.1.2 Antibodies 
Antibodies (anti-human) for FACS and immunohistochemistry 
Target (Human) Manufacturer Label Clone Method/Concentration 
P75NTR BD None/Biotin C40-1457 IHC, IF (fz, ffpe) *, 1-10 µg/ml 
P75NTR BD PE C40-1457 FACS, 2.5 µg/m 
P75NTR Sigma None ME 20.4 FACS, IHC (fz), 1-1 0µg/ml 
FDC DAKO None CNA.42 IHC, IF (fz, ffpe), 10 µg/ml 
BDNF R&D None 35928 IHC, IF (fz), 10 µg/ml 
TRKB R&D None 72509 IHC, IF (fz), 10 µg/ml 
CD4 BD FITC/PerCP RPA-T4 FACS 1/25 – 1/50 
CD8 BD FITC/PerCP RPA-T8 FACS 1/25 – 1/50 
CD14 BD FITC/PerCP M5E2 FACS 1/25 – 1/50 
CD19 DAKO FITC HD37 FACS 1/25 – 1/50 
CD20 BD FITC/PerCP L27 FACS 1/25 – 1/50 
CD21 DAKO FITC 1F8 IHC, IF (fz, ffpe), 1-10 µg/ml 
CD27 BD FITC M-T271 FACS  1/50 
CD38 BD FITC HIT2 FACS 1/50 
CD56 BD None MY31 FACS 1/25 – 1/50 
CD77 BD FITC B5B FACS 1/50 
CD79a DAKO None CJB117 IHC, IF (fz, ffpe), 1-10 µg/ml 
IgM BD FITC G20-127 FACS 1/25 – 1/50 
IgD BD FITC IA6-2 FACS 1/25 – 1/50 
 
Isotype controls 
Isotype Manufacturer Label Method/Concentration 
Mouse IgG1 BD FITC/PE/PerCP FACS 1/25 – 1/50 
Mouse IgG2a BD FITC/PE/PerCP FACS 1/25 – 1/50 
Mouse IgG2b BD FITC/PE/PerCP FACS 1/25 – 1/50 
Mouse IgM DAKO None IHC, IF (fz, ffpe), 1-10 µg/ml 
Mouse IgG1 DAKO None/Biotin IHC, IF (fz, ffpe), 1-10 µg/ml 
                                                
* fz: frozen, ffpe: formalin fixed paraffin embedded, IHC: Immunohistochemistry, IF: Immunolorescence 
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Antibodies (anti-mouse) for immunohistochemistry 
Target (Mouse) Manufacturer Label Clone Method/Concentration 
P75NTR Serotec None ab8874 IHC, IF (fz)*, 0.1-1 µg/ml  
IgM Jackson Cy5 - IF (fz), 1-10 µg/ml 
IgD eBiosciences Biotin 11-26c IF (fz), 1-10 µg/ml 
B220 BD FITC RA3-6B2 IF (fz), 1-10 µg/ml 
FDC BD None FDC-M1 IHC, IF (fz), 10 µg/ml 
CD4 Invitrogen Alexa-488 RM4-5 IF (fz), 1-10 µg/ml 
CD8 Invitrogen Alexa-488 5H10 IF (fz), 1-10 µg/ml 
 
Antibodies (anti-mouse) for ELISA 
Target (Mouse) Manufacturer Label Clone Method/Concentration 
IgG1 BD Biotin A85-1 ELISA detection 1 µg/ml 
IgG1 BD None A85-3 ELISA coating 1 µg/ml 
IgG2a/2b BD Biotin R2-40 ELISA detection 1 µg/ml 
IgG2a  BD None R11-89 ELISA coating 1 µg/ml 
IgG2b  BD None R9-91 ELISA coating 1 µg/ml 
IgM BD Biotin R6-60.2 ELISA detection 1 µg/ml 
IgM BD None II/41 ELISA coating 1 µg/ml 
IgG Jackson None Goat  ELISA detection 1 µg/ml 
IgG Jackson HRP Goat ELISA coating 1 µg/ml 
IgM Jackson None Goat ELISA detection 1 µg/ml 
IgM Jackson HRP Goat ELISA coating 1 µg/ml 
                                                
* fz: frozen, ffpe: formalin fixed paraffin embedded, IHC: Immunohistochemistry, IF: Immunolorescence 
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Antibodies (anti-mouse) for FACS 
Target (Mouse) Manufacturer Label Clone Method/Concentration 
Specificity Company Label Clone FACS 0.5 µg/ml 
CD11b Pharmingen PE M1/70 FACS 0.5 µg/ml 
CD19 Pharmingen FITC 1D3 FACS 0.5 µg/ml 
CD19 Pharmingen PE 1D3 FACS 0.5 µg/ml 
CD45R/B220 Pharmingen PerCP RA3-6B2 FACS 0.5 µg/ml 
CD8a Pharmingen APC 53-6.7 FACS 0.5 µg/ml 
CD4 Pharmingen PerCP RM4-5 FACS 0.5 µg/ml 
CD25 Pharmingen PE 3C7 FACS 0.5 µg/ml 
CD62L Pharmingen Biotin MEL-14 FACS 0.5 µg/ml 
IgMb Pharmingen FITC, PE AF6-78 FACS 0.5 µg/ml 
MHC Class II I-A/I-E Pharmingen Biotin 2G9 FACS 0.5 µg/ml 
FAS Pharmingen PE Jo2 FACS 0.5 µg/ml 
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4.1.3 PRIMERS AND PROBES 
a. Conventional PCR primers 
Human GAPDH - Reference gene (RG). 
Forward primer:  5’-GAAGGTGAAGGTCGGAGTC-3’ 
Reverse primer:  5’-GAAGATGGTGATGGGATTTC-3’ 
Amplicon length:  326 bp 
 
Human NGFR Death domain 
Forward primer:  5’-AAAACTCCACAGCGACAGTGGC-3’  
Reverse primer:  5’-AGTGGACTCACTGCACAGACTC-3’ 
Amplicon length:  369 bp 
 
Human NGFR Intracellular domains 
Forward primer:  5’-GCCTTGTGGCCTACATAGCCTT-3’  
Reverse primer:  5’-AGTGGACTCACTGCACAGACTC-3’ 
Amplicon length:  473 bp 
 
Human NGFR Neurotrophin binding and stalk domains 
Forward primer:  5’-CCGTGTGTGAGCCCTGCCTGGA-3’ 
Reverse primer:  5’-AAGGCTATGTAGGCCACAAGGC-3’ 
Amplicon length:  656 bp 
 
Human NTRK1 
Forward primer:  5’-ATGTCACCAGTGACCTCAACAG-3’  
Reverse primer:  5’-GTGGAGAAGAAGGACGAAACAC-3’  
Amplicon length:  485 bp 
 
b. Quantitative TaqMan PCR primers and probes 
Human NGFR  
Forward primer:  5’-CCTGGCTGCTGTGGTTGTG-3’ 
Reverse primer:  5’-CTGTTGGCTCCTTGCTTGTTCT-3’ 
Probe:   5’-FAM-CCTACATAGCCTTCAAGAGGTGGAACAGCTG-TAMRA-3’ 
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Human NTRK1  
Forward primer:  5’- GAAGAGTGGTCTCCGTTTCGTG -3’ 
Reverse primer:  5’- GAGAGAGACTCCAGAGCGTTGAAG -3’ 
Probe:   5’-FAM-ACTCCTCGGCTCAGTCGCCTGAATCTCT-TAMRA-3’ 
 
Human NTRK2 
Forward primer:  5’-AGGAGAAGATCAAGATTCTGTCAA-3’ 
Reverse primer:  5’-GGTCTGAGGTTGGAGATTCG-3’ 
Probe:   5’-FAM-ACTGTGCATTTTGCACCAACTATCACATTTCT-TAMRA-3’ 
 
Human NTRK3  
Forward primer:  5’-GACAATGGCTTCACCCTGAC-3’ 
Reverse primer:  5’-CAGCTCAGGCTCCTCCAG-3’ 
Probe:   5’-FAM-ATGCCAGTGTTGCCCTCACTGTCTACTATC-TAMRA-3’  
 
Human CD79A 
Forward primer:  5’-CACCAAGAACCGAATCATCACA-3’ 
Reverse primer:  5’-GAGATGTCCTCATACATGGAGCA-3’ 
Probe:   5’-FAM-TCGTCCAGGTTCAGGCCTTCATAAAGGTT-TAMRA-3’ 
 
Human GAPDH  
Forward primer:  5’-GAAGGTGAAGGTCGGAGTC-3’ 
Reverse primer:  5’-GAAGATGGTGATGGGATTTC-3’ 
Probe:   5’-FAM-CAAGCTTCCCGTTCTCAGCC-TAMRA-3’ 
 
PPIA (peptidyl-prolyl isomerase A - cyclophilin A), GAPDH, BDNF, SORT1 
(Sortilin), RTN4R (Nogo Receptor) primers and probes were purchased from Applied 
Biosystems. Other primers and probes are self designed using Primer3 (Steve Rozen 
and Helen J. Skaletsky 2000) and Primer Express v1.0 (Applied Biosystems). All 
primer/probe sequences are controlled for self-complimentarity or possible 
interactions with each other. Designed primers are tested with conventional PCR 
experiments to amplify from cDNA but not genomic DNA. 
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4.2 Methods 
 
4.2.1 Cell preparations 
Experiments were performed with freshly isolated human peripheral blood 
mononuclear cells (PBMCs). 2x106 cells per ml were used for all functional assays. 
 
4.2.2 Cell separations 
1. PBMCs were separated into different subtypes as CD4+ and CD8+ T 
lymphocytes, CD19+ B lymphocytes, CD56+ Natural Killer (NK) cells and CD14+ 
monocytes using magnetic beads by positive or negative selection (Dynal or Miltenyi 
Biotec/MACS). The purity of the isolated cell types was between 90-96% for different 
cell populations as determined by FACS analysis (BD FACSCalibur). 
2. Adenoid B cell isolation: Fresh adenoids were cut into 2x2 mm pieces and 
the pieces were passed through 40 or 70 µm cell strainer (BD Falcon). Mononuclear 
cells (MNCs) were isolated by density gradient centrifugation (Pancoll, PAN Biotech). 
B cells were separated using CD19 positive cell isolation kit (Dynal or Miltenyi 
Biotec/MACS). 
 
4.2.3 Cell activation / stimulation 
PBMCs or subpopulations were activated with different mitogens or cytokines 
to analyze various responses as proliferation, differentiation, modulation of 
expression pattern of some proteins (cytokines/receptors, CD markers etc.). 
T cell activation 
1. ConA (Sigma): final concentration 10 µg/ml. 
2. PMA + Ionomycin (Sigma) PMA: final concentration 3 ng/ml, Ionomycin: 
final concentration 300 ng/ml. 
3. Anti-CD3 (Dako) 1 µg/ml 
B cell activation 
1. SAC (Staphylococcus Aurous Cowan 1 antigen) (Calbiochem) Dilution: 1:7500. 
2. CD40L (R&D) 
3. PWM (Pokeweed mitogen) (Sigma): final concentration 5 µg/ml. 
4. LPS (Only for mouse B cells) 
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Monocyte activation 
After 24 hr in culture monocytes were activated as follows. 
LPS (Lipopolysaccharides from E.coli) (Sigma), final concentration 300 ng/ml. 
1. IFN-γ (Interferon-gamma) (Roche), final concentration 100 U/ml. 
2. TNF-α (Tumor Necrosis Factor-α) (Roche), final concentration 50-100 U/ml. 
3. GM-CSF (Granulocyte–Macrophage Colony Stimulating Factor) (R&D), final 
concentration 250 ng/ml. Culture 7-9 days for macrophage differentiation. 
 
4.2.4 Cell lines 
Cell lines were used as positive controls for protein and mRNA expression of 
p75NTR; they were also used to test functional effects of NTs and ProNTs. Cell lines 
were cultured in 25 or 75 cm2 Falcon flasks with 5%-10% FCS (Gibco), in RPMI 
(Gibco) medium + 1% penicillin (50-100 U/ml)/streptomycin (50-100 µg/ml). Incubator 
settings were 37°C, 95% humidity, 5% CO2. 
SH-SY5Y - Human neuroblastoma clonal sub-line of the neuroepithelioma cell 
line SK-N-SH that had been established in 1970 from the bone marrow biopsy of a 4-
year-old girl with metastatic neuroblastoma. 
SK-N-MC - Human neuroblastoma established from the supraorbital 
metastasis of a neuroblastoma of a 14-year-old girl in 1971. 
REH - Human B cell precursor leukemia established from the peripheral blood 
of a 15-year-old girl with acute lymphoblastic leukemia. 
 
4.2.5 FACS analysis 
For intracellular staining, cells were fixed and permeabilized using cell 
permeabilization buffer. Dead cells and debris were excluded from the analysis by 
Via-Probe (BD) or forward/side scatter settings. Data were analysed with CellQuest 
(BD Biosciences) or FlowJo flow cytometry analysis software (Tree Star, Inc.). 
 
4.2.6 ELISA 
ELISAs were used to measure cytokines (IL-6 and MCP-1) produced by immune 
cells or serum immunoglobulin (IgG1, IgG2a, IgG2b, IgM, IgE, IgA, IgG or total Ig) 
levels of mice. 
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4.2.7 RNA Extraction 
RNA Extraction from formalin fixed paraffin embedded material using Trizol 
- Collect 10 sections each 4 µm thick in a 2 ml RNase free tube 
- De-paraffinize: Wash 2x10 min xylene, 100%, 90%, and 70% ethanol 5 min 
- Place the tubes (caps open) in heat block 37°C for 10-15 min to evaporate ethanol 
- Add 200 µl lysis buffer; incubate overnight (16 hours) at 56°C 
- Add 1 ml Trizol (for 200 µl lysis buffer); incubate for 5 min at room temperature (RT) 
- Add 200 µl chloroform, shake vigorously for 15 sec and incubate 15 min at RT 
- Centrifuge 15 min, 11000 rpm*, at 4°C, take upper aqueous phase in a new tube 
- Add 0.5 ml isopropanol and mix well, incubate 10 min at RT 
- Centrifuge 10 min, 11000 rpm*, at 4°C 
- Remove supernatant, wash pellet with 1 ml 75% ethanol and vortex 
- Centrifuge 5 min, 8500 rpm*, at 4°C 
- Remove SN, air dry the pellet for 5-10 min 
- Add water to dissolve RNA, heat to 56°C if necessary 
 
RNA Extraction from fresh cells or frozen material with Qiagen RNeasy kit 
- Add 600 µl buffer RLT for 5-10 million cells or 10-15 sections each 10 µm thick, mix 
and eliminate visible debris by pipetting, do not vortex. 
- Transfer lysate to QIAshredder column spin 14000 rpm*, 2 min at RT 
*- Add 600 µl 70% ethanol to lysate and mix with pipetting 
- Transfer 600 µl of this solution to RNeasy column, spin 10000 rpm*, 20 sec at RT, 
discard follow-through (dft) 
- Transfer remaining 600 µl to RNeasy column; spin 10000 rpm*, 20 sec at RT, dft 
- Add 350 µl buffer RW1 to column; spin 10000 rpm*, 20 sec at RT, dft 
- Add 80 µl DNase solution (70 µl Buffer RDD + 10 µl DNase) incubate 15 min at RT 
- Add 350 µl buffer RW1 to column; spin 10000 rpm*, 20 sec at RT, dft 
- Use new collection tube; add 500 µl Buffer RPE, spin 10000 rpm*, 20 sec at RT, dft  
- Add 500 µl buffer RPE and spin 10000 rpm*, 2 min at RT, dft 
- Use 1.5 ml tube to place the column, add 20-40 µl water directly on membrane and 
spin 10000 rpm*, 1 min at RT 
                                                
* Centrifuge used: Eppendorf 5417R 
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RNA concentration was determined by measuring the absorption at 260nm 
and 280nm. A280 is used as a measure of impurity of DNA (A280/A260 should be 
between 1.8 and 2.0). Spectrometers used: Nanodrop and Eppendorf photometer. 
 
4.2.8 Reverse transcription 
Complimentary DNA (cDNA) was synthesized using the reverse transcriptase 
kit (MML-V, Promega), according to manufacturer’s protocol. 
 
4.2.9 PCR (polymerase chain reaction) analysis 
The cDNA obtained after reverse transcription reaction is used for PCR. 
Electrophoresis of PCR products was done using 1.5% agarose gels. For sequencing 
reactions, DNA amplified by PCR was purified using PCR purification kit (Qiagen) 
according to the manufacturer’s protocol. Sequencing of purified DNA from PCR 
products were performed by Sequiserve, Martinsried. 
 
4.2.10 Quantitative PCR 
Quantitative PCR was performed on the GeneAmp5700 or GeneAmp7300 
(Applied Biosystems-ABI) using the qPCR Core kit and UNG (Uracyl-N-glycosylase 
for carry-over prevention) (both Eurogentec). The reaction volume was 25 µl 
containing 25 – 50 ng RNA converted to cDNA. For all reactions an annealing 
temperature of 60ºC has been considered for reverse and forward primers and 70ºC 
for probes. For detection of target genes, primers and probes were designed and 
were tested for efficiency, additionally; genomic DNA has been used as a template to 
confirm that it is not amplified (Refer to primer/probe table for complete list of gene 
expression assays). GAPDH and PPIA (Cyclophilin A) were selected as reference 
genes (RG). Relative quantification were calculated using the formula: %RG = 100 × 
2(-ΔCt), where ΔCt is the differende between cycle threshold values of RG and gene of 
interest (GOI). Combined standard deviation (Sd) of RG and GOI were calculated 
using the formula based on Muller et al. (2002). 
Sd = 100 × (2Ct RG/2Ct GOI) × ((LN2 × Sd RG)2 + (LN2 × Sd GOI)2)1/2 
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4.2.11 Immunohistochemistry 
Materials that were used for immunohistochemistry: 
Human:  - Frozen tonsil, adenoid and spleen. 
- Formalin fixed paraffin embedded adenoid, healthy thyroid, 
Hashimoto’s Thyroiditis and follicular B cell lymphoma cases. 
Mouse: - Frozen spleen, frozen lymphnode. 
 
For frozen material, Superfrost (Menzel) slides were used. 10µm frozen 
sections were air dried and fixed with 4% PFA, incubated in Methanol + 3% H2O2 to 
stop endogenous peroxidase activity, washed with 1X PBS, and blocked with 10% 
FBS + 5% serum from secondary antibody host species in 1X PBS. Sections 
incubated with primary antibodies for 1 hour at room temperature and washed with 
1X PBS. PAP or sABC amplification and DAB development step (all from Dako) 
performed according to the manufacturer’s protocol. Hemalaun (Merck) has been 
used for nuclear counterstaining. Aqueous mounting medium (Dako) and cover slips 
(Menzel) used to finish preparation. 
For formalin fixed and paraffin embedded material, 4 - 7 µm thick sections 
were prepared on Superfrost/Plus (Menzel) slides. After deparaffinization step 
(incubation of sections 2 times for 10 minutes in xylene followed by 5 minutes in 
100%, 90%, 70% and 50% ethanol), slides were washed with 1X PBS. For epitope 
retrieval, slides were kept in 95°C citrate buffer (10 mM, pH 6.0) for 20 minutes. All 
washing, blocking, antibody incubation and developing steps performed similar to 
cryosection preparations. 
 
4.2.12 Immunofluorescence – Confocal microscopy 
All of the section preparation, fixing, washing, blocking and antibody 
incubation steps were performed as described above in immunohistochemistry 
section. As secondary antibodies, goat anti-mouse Alexa488 and Alexa594 
(Molecular probes), goat anti-mouse (Fab) CY3 and CY5 (Jackson Labs), 
streptavidin CY5 (Jackson Labs) were used. The nuclei were counterstained with 1 
µg/ml DAPI (Sigma-Aldrich). As isotype control, mouse IgG1 (Dako Cytomation, 
Sigma-Aldrich) and mouse IgM (Cymbus, Dako Cytomation) were used. Confocal 
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images were taken with a DM-IRE2 laser scanning microscope (Leica) using Leica 
confocal software version 2.61, Build 1537. 
 
4.2.13 Laser capture microdissection (LCM) 
10 µm cryostat sections from freshly frozen adenoids were mounted on PET-
slides (P.A.L.M Microlaser). Slides were dried for 30 min at RT protected from air 
current or dust and 30 min at 37°C, and stored at -80°C. For LCM, sections were 
rehydrated with DEPC-PBS for 10 min. In order to visualize lymphoid follicles, 
nuclear stainings were performed with Hemalaun (Merck) for 5 seconds; slides were 
rinsed in DEPC water and stored in closed containers with silica-gel (Merck). Dense 
nuclear stainings of the mantel zone were used to guide the laser beam around 
follicles (Fig. 4.2). 10 µl RNase free filter tips were used to collect the dissected 
material because the areas were too big to be catapulted by laser pressure. 
Collected material was carefully placed in a tube and stored on dry ice/-80°C until 
RNA isolation with phenol-chloroform extraction method. 
 
  
Figure 4.2 
Dense Hemalaun staining of the mantel zone served as a border for the laser. 
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4.2.14 Animals 
 Animals with C57BL/6 background were used in the study. P75NTR (Ngfr) exon 
IV knockout (von Schack et al., 2001) and wild type mice were imported from MRC 
Toxicology Unit, University of Leicester, United Kingdom. All mice were maintained in 
the conventional and SPF animal facilities of Max-Planck-Institute of Neurobiology, 
Martinsried, Germany. Mice will be noted as wild type (WT) and knockout (KO) for 
wild type and p75NTR exon IV knockout mice respectively 
 
Table 4.1 List of mice used for experiments 
 
Wild type mice    Knockout mice 
 
Sex ID. 
Number 
Ear 
marking 
Birth 
date 
 Sex ID. 
Number 
Ear 
marking 
Birth 
date 
M 10.1.2 LEM 07.04.06  F 7.1.7 REM 06.03.06 
M 10.1.4 2REM 07.04.06  F 7.1.8 LEM 06.03.06 
F 10.1.5 REM 07.04.06  F 7.1.9 BEM, 06.03.06 
F 10.1.6 LEM 07.04.06  M 8.1.1 REM 25.03.06 
F 10.2.9 BEM 03.05.06  M 8.1.2 LEM 25.03.06 
F 10.2.10 2REM 03.05.06  M 8.1.3 BEM 25.03.06 
F 9.3.10 BEM 20.05.06  F 8.1.4 REM 25.03.06 
F 9.3.10 3R2LEM 20.05.06  F 8.1.5 LEM 25.03.06 
F 6.6.3 REM 20.05.06  M 7.2.2 LEM 12.05.06 
F 6.6.4 LEM 20.05.06  M 7.2.4 2REM 12.05.06 
M 9.3.1 REM 20.05.06  M 7.2.5 2LEM 12.05.06 
M 9.3.3 1R2LEM 20.05.06  M 7.3.1 REM 09.06.06 
M 9.3.2 LEM 20.05.06  M 7.3.2 LEM 09.06.06 
M 10.3.2 2LEM 31.05.06  M 7.3.3 BEM 09.06.06 
M 10.3.5 2L1REM 31.05.06  F 7.3.4 REM 09.06.06 
M 11.2.5 2LEM 15.06.06  F 7.3.5 LEM 09.06.06 
M 11.2.3 BEM 15.06.06  F 7.3.6 BEM 09.06.06 
 
(LEM: Left ear marking. REM: Right ear marking. BEM: Both ear marking.) 
 
4.2.16 Genotyping 
 KO mice were genotyped by conventional PCR method using primers as 
described by von Schack et al., 2001. Genomic DNA has been extracted from a small 
piece of tail that was clipped after weaning. 
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PCR Primers 
1. 5’-AAGGGGCCACCAAAGAACGG-3’ 
2. 5’-TGTTGGAGGATGAATTTAGGG-3’ 
3. 5’-GATGGATCACAAGGTCTACGC -3’ 
 
Gel electrophoresis 
10 µl template and 2 µl 6x loading buffer were pipeted to each well of a 1.5% 
agarose gel. Run was performed for 40 min at 70 V. Expected product sizes are 500 
bp and 350 bp for wild type and knockout respectively (Fig. 4.3).  
 
 
Figure 4.3 
Genotyping of Ngfr genes by PCR: the 500 bp fragment is 
derived from the wild type and 350 bp band from the mutant 
gene. In case of two bands, the mouse is heterozygous. 
 
 
4.2.17 Immunization 
Sheep red blood cells (SRBC) 
Sheep red blood cell immunization is a well-established method for the 
induction of a strong germinal centre response. Purified SRBC (Fiebig 
Nährstofftechnik, Idstein, Germany) were injected at 5x109 cells/ml in PBS intra-
peritoneally (i.p.). A total volume of 200 µl (1x109 SRBC) was injected to each animal. 
Non-immunized and 7, 14, 21 day immunized WT and KO mice were used for 
experiments. 
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Virus like particles (VLP) 
Virus like particles (VLP) of cytomegalovirus (CMV) occur during viral 
replication in cell culture. VLP lack DNA and only contain fragments of capsid, so 
they are not infectious. VLP were applied intravenous and 5 µg VLP in 200 µl PBS 
(25 µg/ml) used for a single immunization. A booster injection was done 60 days later 
and a concentration of 10 µg/ml has been used. Another group of mice was 
immunized to monitor the primary Ig response. A VPL concentration of 10 µg/ml was 
used for this purpose. 
To obtain VLPs, human foreskin fibroblasts (HFF) were infected with human 
CMV and kept in the incubator for approximately 10 days. Later, supernatant was 
ultracentrifuged (10–40% sucrose density gradient centrifugation at 94.500 g for 60 
min, the band material was collected and pelleted by centrifugation at 155.000 g for 
60 min); virions, dense bodies and non-infectious particles were separated using a 
sodium-tartrate-gradient (Talbot and Almeida, 1977). VLPs were kindly provided by 
Prof. Thomas Winkler (University of Erlangen). 
The utilization of VLP for the immunization has two main advantages. Firstly, 
VLP do not require being co-injected with an adjuvant, leading to a more specific 
response, and secondly, the availability of capsid glycoprotein-B allows very sensitive 
ELISA detection of antigen specific antibodies. 
 
Ovalbumin (OVA) 
Ovalbumin was emulsified in complete Freund's adjuvant (CFA). The final 
concentration was 1 µg/ml and the injections were done subcutaneously (s.c.), 100 µl 
per mice. A booster injection was done 60 days later and a concentration of 1 µg/ml 
used. For the booster injection incomplete Freund's adjuvant (IFA) was used as 
adjuvant. Additional to boosting assay, a second group of mice was immunized for a 
primary Ig response. A concentration of 1 µg/ml OVA+CFA was used for this 
purpose. 
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4.2.18 Serum collection 
Mice were bled by retro-orbital puncture and blood was collected with a glass 
capillary. Samples were kept overnight at 4°C. Serum was collected after 
centrifugation at 4°C / 1 g for 10 min and stored at -20°C until further analysis. 
 
4.2.19 Isolation of splenocytes 
Spleens of KO and WT mice were homogenized and passed through 40 µm 
cell strainers (BD). Cells were centrifuged and red blood cells (RBCs) were 
eliminated by RBC lysis buffer (Qiagen). After recovery of the isotonicity, isolated 
splenocytes were counted and prepared for FACS analysis. 
 
4.2.20 Statistical analysis 
Data are represented as the mean (or average) of at least three values (actual 
number of biological samples and repeated experiments are always indicated below 
each figure). 
Error bars represent either standard deviation (Sd) or standard error of the 
mean (SEM), calculated as following: SEM = Sd / √n. For calculation of statistical 
significance, Mann-Whitney u-test or Student T-test has been used (paired, two-
tailed). P values smaller than 0.01 were considered as highly significant and marked 
with two asterisks (**) and P values smaller than 0.05 were considered as significant 
and marked with one asterisk (*). Statistical calculations were made by Microsoft 
Excel or GraphPad Prizm v4.0. 
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5. RESULTS 
 
5.1. Human study 
Studies focussing on p75NTR are addressed to central and peripheral 
nervous systems in most of the cases, where neurotrophins and neurotrophin 
receptors are expressed constitutively and have their main functions. Very 
detailed expression profiles for various cell types localized in anatomically distinct 
areas of CNS and PNS have been done. When scientists investigated other 
organ systems, tissues or cells, new candidates that can secrete or respond to 
NTs have emerged. There are many reports about the expression of the NGF 
family of neurotrophic factors and their receptors in immune cells and organs, 
dated back to the initial period when the NTs and NTRs were newly identified. 
Unfortunately, it is hard to deduce a clear expression profile due to inconsistency 
among publications. The lack of highly specific monoclonal antibodies or 
advanced detection techniques was the main drawback. Therefore it was 
necessary to investigate the expression pattern on each immune cell subset, 
both at the transcript and protein level. Three different primer pairs and three 
different monoclonal antibodies against human p75NTR were used in this study. 
 
5.1.1 All exons encoding the functional domains of p75 NTR are expressed in 
PBMCs and immune organs 
P75NTR protein has three major domains that interact with ligands or 
adapter proteins. The neurotrophin binding domain, intracellular juxta-membrane 
domain and the death domain (Fig 5.1A). Two different sets of primers were used 
to detect coding regions of the transcript for functional domains (Fig 5.1A). 
Resting and activated immune cell subsets possess all functional domains coded 
by NGFR gene. Similar result was obtained for adenoid and tonsil (Fig 5.1B). S-
p75 or any other splice variants were not detected in PBMCs or immune organs. 
This short isoform is called s-p75 and had only been reported in mouse (von 
Schack et al., 2001, Ibanez 2002). 
 
Results  40 
 
 
Figure 5.1:  
Immune cell subsets and immune organs transcribe full-length p75NTR. P75NTR gene transcript 
consists of 6 exons (A); Exon 1: Signal peptide. Exon 2: Cysteine rich domain 1 (CRD). Exon 3 
CRD 2-3-4 also called as neurotrophin binding domain (NTBD). Exon 4: Stalk domain (SD) and 
trans-membrane domain (TMD). Exon 5: Juxta-membrane domain (JMD). Exon 6: Death domain 
(DD). Amplicon-1: 656 bp coding NTBD, SD and TMD; Amplicon-2 473 bp coding JM and DD. 
Various immune cell subsets express p75NTR (B) Lanes: 1. CD4+ T cells, 2. CD4+ T cells + PMA-
Ionomycin, 3. CD8+ T cells, 4. CD8+ T cells + PMA-ionomycin, 5. CD56+ NK cells, 6. CD56+ NK 
cells + IL2, 7. CD19+ B cells, 8. CD19+ B cells + pokeweed mitogen (PWM), 9. adenoid CD19+ B 
cells, 10. adenoid CD19+ B cells + PWM, 11. monocytes, 12. monocytes + LPS, 13. 
macrophages, 14. macrophages + LPS and immune organs 17. Tonsil and 18. adenoid transcribe 
full-length p75NTR gene. Peripheral nerve (lane 19) and CNS (lane 20) tissues were used as 
positive control. Lane 15 is no template control and lane 16 is genomic DNA control. 
Activation/stimulation period was 24 hour. There was no signal on the 250 bp marked with the 
white arrow (B, upper panel, left side), concluding that there is no detectable expression of s-p75 
in immune cells and organs. Any other immune specific splice variant could not be detected. 
 
5.1.2 Expression of p75 NTR in PBMCs  
In order to better identify the distribution of p75NTR expression on various 
cell subsets, PBMCs were magnetically separated to obtain highly purified cell 
populations (with a minimum purity of 91%, data not shown). CD4+ T cells, CD8+ 
T cells, CD14+ monocytes, CD19+ B cells and CD56+ NK cells (Natural killer) 
were analysed for p75NTR expression ex vivo, and in culture in a resting or 
activated state. In all cell subsets, p75NTR expression was detectable by PCR 
analysis (Fig 5.1B). FACS analysis was performed to assess corresponding 
protein expression levels in each subset (Fig 5.3). In total, 4%, 16% and 20% of 
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CD4+, CD8+ and CD56+ cells expressed p75NTR respectively, whereas monocytes 
and B cells did not show any reactivity by FACS (Table 5.1) with two different 
monoclonal antibodies against p75NTR.  
 
Table 5.1  
The percentage of p75NTR positive cells in PBMC. 
 
In unseparated PBMCs, 8% of the cells are p75NTR positive. The main population forming this 
group are CD4+, CD8+ T cells and CD56+ NK cells. After lineage marker specific cell isolation, 
these subsets were further analysed individually.  20% of CD56+ NK cells, 16% of CD8+ T cells 
and 4% of CD4+ T cells were found to express p75NTR. 
 
Quantitative PCR analysis showed that P75NTR mRNA expression was 
enhanced upon T cell activation (Fig 5.2). B cells and monocytes only had very 
low expression and an upregulation was not observed following activation (Fig. 
5.2). A weak induction was detected observed NK cells following IL-2 stimulation. 
Induction of p75NTR in CD4+, CD8+ and CD56+ cells were confirmed by flow 
cytometry (Fig. 5.3). 
 
Figure 5.2 
Expression of p75NTR in immune cell populations has been analysed by TaqMan PCR. In 
peripheral blood CD8+ T cells and CD56+ NK cells are the main cell populations expressing 
p75NTR. PMA-Ionomycin activation (24 h) of CD8+ and CD4+ T cells resulted in induced 
expression of p75NTR. With IL-2 stimulation (24 h), just a slight induction of p75NTR 
expression in CD56+ NK cells were observed. Monocytes and macrophages had a low 
basal expression, which does not change upon activation (24 h) with LPS or IFNγ (data not 
shown). One representative result out of 2-7 independent experiments is shown. Columns 
represent p75NTR relative mRNA expression to reference gene (Cyclophilin A). Error bars 
indicate combined standard deviation of reference gene and p75NTR, calculated using 
replicates. 
PBMC CD4+ CD8+ CD14+ CD19+ CD56+ 
8% 4% 16% <1% 0% 20% 
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Figure 5.3 
P75NTR expression in T cells is induced upon activation. FACS analysis of magnetically separated 
cell populations: After activation of CD4+ and CD8+ T cells with PMA+Ionomycin for 24 h, p75NTR 
expression is induced on both T cell populations, especially on CD8+ T cells. Values in the inner 
corners indicate percentage of cells in respective quadrant. One representative result out of 3 
independent experiments is shown. Values located on the corner of each quadrant represent 
percentage of cells in respective area. Representative result out of 4 independent experiments. 
 
 
5.1.3 P75NTR mRNA levels of immune organs vs CNS tissue 
After mapping the p75NTR expression of human PBMC subsets, mRNA 
levels of immune organs were compared to CNS tissue. Various regions of 
human CNS (grey matter, white matter, cerebellum and cortex) were used to 
extract RNA and prepare cDNA. Adenoid, tonsil and spleen samples were 
analysed and they had similar mRNA level compared to CNS tissue (Fig 5.4).  
The lowest amount of transcript was observed in PBMC. 
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Figure 5.4 
P75NTR mRNA levels in CNS and immune organs were compared by TaqMan PCR. 
CNS and immune organs expressed similar levels of p75NTR. Data points of CNS 
represent different sample preparations from cortex (n=3), white matter (n=3), grey 
matter (n=3) and cerebellum (n=2). All CNS tissue were obtained from 3 
individuals. Ananlyzed immune organs are spleen (n=1) adenoid (n=2) and tonsil 
(n=2). PBMCs were obtained from blood of healthy donors (n=3). PPIA (Cyclophilin 
A) was used as reference gene. 
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5.1.4 Expression of p75 NTR on adenoid B cells 
In order to identify the source of p75NTR expression in secondary lymphoid 
organs, a series of experiments were conducted. First, mononuclear cells (MNC) 
from fresh human adenoids were isolated by density gradient method and 
analysed by FACS. About 11% of total adenoid MNCs were positive for p75NTR. 
Almost all p75NTR positive cells were identified as B cells (Fig. 5.5). Among other 
mononuclear cells, a detectable signal was obtained only from CD8+ cells (1% 
positive; data not shown).  
A 
 
Figure 5.5 
Peripheral blood CD19+B cells do not express p75NTR, but a subset of adenoid B cells 
does (A). 10% of unseparated adenoid cells express p75NTR. Quantitative PCR 
analysis of purified blood and adenoid B cells showed similar results (B), n=3 for both 
groups. Represantative FACS figures from one experiment out of 3. Error bars 
represent combined standart deviation of reference gene PPIA (Cyclophilin A) and 
p75NTR. 
B 
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 In order to classify p75NTR expressing adenoid B cells, further surface 
staining of purified CD19+ cells using antibodies directed against well-defined B 
cell markers were performed (Fig. 5.6). 
 
 
Figure 5.6 
CD19+ B cells were isolated from fresh adenoids and analysed by flow cytometry for the 
expression of p75NTR. About 16% of magnetically purified CD19+ adenoid B cells express 
p75NTR. In order to better classify p75NTR+ cells, IgM+, IgD+, CD27+ (memory B cells), CD38+ 
(germinal centre B cells) and CD77+ (centroblasts) cells were analysed. The majority of 
p75NTR+ cells express CD38 and not CD77. About 50% of p75NTR+ cells are also positive for 
IgM, IgD or CD27. Mouse IgG1 isotype control used to determine quadrant positions for 
CD38 and CD27, mouse IgG2a isotype control (not shown) used for IgM and IgD, mouse 
IgM isotype control (not shown) used for CD77. A representative result from 3 independent 
experiments is presented. Values on the corner of each quadrant represent percent of cells 
in each quadrant. 
 
 
Membrane proteins representing different maturation stages of the 
adenoid B cells were targeted in parallel with p75NTR. P75NTR was distributed on 
memory B cells (CD27+), germinal centre B cells (CD38+), IgM+ B cells and IgD+ 
B cells. On the other hand plasma cells (CD138+) (data not shown) and 
centrocytes (CD77+) were negative. With the selection of B cell markers that 
were used, it was not possible to identify a unique p75NTR expressing population. 
From the expression pattern, we deduce that p75NTR is present on a subset of 
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GC B cells and since CD77+ centroblasts are negative, the receptor is present 
during later stages of maturation. 
 
5.1.5 p75NTR expression in lymphoid organs 
 In order to map the distribution of p75NTR expression in human immune 
organs, we used frozen and formalin fixed paraffin embedded (FFPE) material 
and two different mAbs. Both mAbs against p75NTR showed a very similar 
staining pattern of germinal centres in tonsils and adenoids (Fig 5.7). In parallel 
with our flow cytometry results, we could not observe specific p75NTR staining in 
the T cell area. 
 
Figure 5.7 
Immunohistological staining of tonsil cryosections were performed with two different mAbs 
against p75NTR. Mouse PAP system (Dako) for signal enhancement, hemalaun counterstaining 
and DAB (Di-amino benzidine - Sigma-Aldrich) substrate were used for visualization. Mouse IgG1 
isotype did not show any sign of unspecific staining (A). MAb C40-1457 (BD biosciences) was 
used in B and mAb ME 20.4 (Sigma-Aldrich) in C and D. Scale bars represent 200 µm in A, B, C 
and 25 µm in D. 
 
Formalin fixed and paraffin embedded (FFPE) material is more instructive 
when visualized because tissue integrity is better preserved. Apart from lymph 
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follicles, basal layer of the squamus epithelium stained positively for p75NTR. 
Additionally, an immunostaining for p75NTR of spleen cryosections was 
performed. A relatively weak signal was detected in follicles, again on some 
lymphocytes and FDC like structures, additionally, central arterioles, other blood 
vessels and splenic macrophages were positive for p75NTR (Fig 5.8). 
 
 
Figure 5.8 
FFPE adenoid tissue (A) and frozen sections of human spleen (B) were probed with a mAb 
against p75NTR (C40-1457). In FFPE adenoid sections additional to the strong follicle staining, 
the basal layer of the squamus epithelium stained positively as shown with black arrow. 
Immunohistological analysis of human spleen showed a different pattern of p75NTR. Marginal 
zone macrophages (m) surrounding the white pulp of splenic nodule, central arterioles in splenic 
nodule (ca), trabecullar artery (ta) stained strongly and cells in the red pulp (rp), presumably 
macrophages and dendritic cells were also positive. Follicular signal (f) in the white pulp was 
rather weak compared to adenoid. Scale bar: 200 µm. 
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Figure 5.9 
Double immunofluorescence assays were performed in human adenoid tissue. A mAb 
to CD21 (clone 1F8) was used as an FDC marker (A) in combination with p75NTR 
antibody (C40-1457) (B) and DAPI nuclear staining. In the overlaid picture (C) double 
positive FDC like structures (arrows) and single p75NTR stained lymphocytes (arrow 
heads) were present. 
 
For the determination of p75NTR expression on different cell types, double 
immunofluorescence technique was used.  Thereby p75NTR could be localized to 
FDC. Additionally, single p75NTR positive cells that were negative for the FDC 
marker were also detected in germinal centres. As a conclusion, FDC and some 
lymphocytes were identified as p75NTR expressing components of lymph follicles 
(Fig 5.9).  
 
5.1.6 Expression of BDNF in lymphoid follicles 
Looking for ligands of p75NTR, we identified BDNF in lymphoid follicles. 
Double labeling showed that BDNF co-localizes to both B cells (CD20+) and FDC 
(CD21+) (Fig. 5.10).  
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Figure 5.10 
BDNF is present in lymphoid follicles. Adenoid cryo-sections were probed with the BDNF specific 
mAb antibody (clone 35928), in parallel with anti-CD21 (clone 1F8) and anti-CD20  (clone L27) 
mAbs as markers for B cells and FDC respectively. A clear staining of lymphoid follicles has been 
observed. Double immuno-fluorescence stainings confirmed co-expression of BDNF with CD21 
and CD20.  
 
Since TrkB is considered as the high affinity receptor for BDNF, immuno-
staining using antibodies against TrkB receptor were also performed. The 
expression was detected more prominently outside of the follicular area, in the T 
cell zone (Fig.  5.11), additionally some macrophages and a weak staining on 
FDC like structures and lymphocytes. The expression pattern of p75NTR and TrkB 
is the opposite: p75NTR is the prominent NT receptor in the lymphoid follicles (B 
cells and FDC) while TrkB seems to be responsible for BDNF signaling outside of 
the follicles (T cells). 
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Figure 5.11 
TrkB expression (brown staining) in human adenoid is more prominent in the T cell area (Tc), 
outside of lymphoid follicle (f) (Monoclonal Anti-human TrkB, clone 72509). Weak expression within 
the follicular area (f) originates from FDCs, lymphocytes and marginal zone macrophages (m). 50x 
magnification, scale bar: 200 µm on the left and 200x magnification, scale bar: 50 µm on the right. 
Hemalaun used as nuclear staining. 
 
 
In order to assess the distribution of BDNF, NGFR and NTRK2 mRNA 
expression in adenoids, frozen sections of adenoids were used for laser micro- 
dissection.  In order to protect RNA integrity, only a fast nuclear staining was 
done by hemalaun to visualize follicles. Dense nuclear staining of the B cell 
population of the mantel zone provided a guideline for the laser beam (1). Similar 
cutting patterns were repeated to collect material from T cell area. After RNA 
extraction from the dissected material, cDNA synthesis and finally for quantitative 
PCR were performed. Obtained results were in accordance with immunostaining. 
BDNF and NGFR transcripts were more abundant in follicles than in T cell area 
and vice versa for NTRK2 (Fig. 5.12).  
                                                
1 Refer to figure 4.3 in Materials and Methods section for additional details about laser microdissection. 
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Figure 5.12 
The mRNA analysis of laser microdissected lymphoid follicles. 10 µm thick frozen human 
adenoid sections were placed on PET slides and dried under RNase free conditions. A fast 
hemalaun staining was performed to visualize lymphoid follicles due to high B cell intensity in 
the mantel zone. 20 tissue pieces obtained from T cell area and 20 lymphoid follicles were 
pooled from three different adenoid samples. Collected material was used for RNA isolation, 
reverse transcription and quantitative TaqMan PCR. Error bars represent combined standart 
deviation of reference gene (GAPDH) and gene of interest. 
 
 
5.1.7 P75NTR is present in extranodal follicles of Hashimoto’s Thyroiditis 
It is well known that extranodal follicles develop during several 
autoimmune diseases like rheumatoid arthritis (RA) or Hashimoto’s thyroiditis 
(HT) (Fig. 5.13). In HT, the immune system attacks the thyroid cells and various 
auto-antibodies against thyroid peroxidase, thyroglobulin and thyrotropin 
receptors may be present in the patient’s sera. Prolonged autoimmune attack to 
the thyroid usually causes hypothyroidism. One of the major characteristics of the 
disease is the occurrence of extranodal lymph follicles in the thyroid tissue (Fig. 
5.13). 
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Figure 5.13 
Several extranodal follicles within the thyroid in Hashimoto’s Thyroiditis. Normal histological 
pattern of thyroid structure is distinguishable on the upper right area in hematoxylin eosin (HE) 
stained tissue section (A). Dense lymphocyte population infiltrated the tissue. Follicular dendritic 
cells in extranodal lymph follicles were stained by p75NTR antibody (C40-1457) (B). P75NTR 
antibody does not stain B cells in paraffin embedded material. (50x magnification) Serial sections 
of extranodal follicles were stained with P75NTR, FDC (CNA.42) and CD79α (CJB117) specific 
mAbs. Mouse IgG1 isotype Ab did not cause any background signal (C). P75NTR staining (E) was 
concentrated in follicular region, similar to adenoid lymph follicles.  Further immuno-stainings for 
B cells (D) and FDCs (F) contributed in understanding the morphology of extranodal follicles. 
Scalebars: A and B 400 µm; C, D, E and F 200 µm. 
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The expression of p75NTR in extranodal follicles has not been reported 
before. For this purpose we compared thyroid tissue samples from healthy 
indiviuals (n=5) and from patients with Hashimoto thyroiditis (n=5). We used both 
immuno-histochemistry and quantitative PCR to access the expression profile of 
p75NTR in extranodal follicles. For all experiments formalin fixed and paraffin 
embedded material was used. Initially, extranodal follicles were identified 
morphologically and then by applying established FDC and B cell markers. Two 
different mAbs against p75NTR performed similarly and showed reactivity with 
FDC like structures (Fig. 5.13). 
A quantitative PCR of 5 HT cases and 5 healthy thyroids showed that 
p75NTR is upregulated in HT (Fig. 5.14). 
 
 
Figure 5.14 
The transcript level of p75NTR was significantly higher in HT samples as compared to 
control thyroid (p<0.05). CD79A was used to mirror B cell presence in the thyroid as a 
positive control for HT. Scale is individually adjusted for each graph, n=5 for each group. 
Cyclophilin A was used as reference gene. Error bars indicate SEM. (* p<0.05, ** p<0.01, 
Mann-Whitney U-test.   
 
 
5.1.8 P75NTR expression in follicular B cell lymphomas 
Another human disease with extranodal follicles is follicular B cell 
lymphoma. BCL-2 translocation is the main feature of the follicular B cell 
lymphoma.  
BCL-2 is located in the membrane of the endoplasmic reticulum (ER), 
nuclear envelope, and in the outer membranes of the mitochondria (Hockenbery 
et al., 1990). In malignant B cells, the region of chromosome 18 containing the 
BCL-2 locus has undergone a reciprocal translocation with the antibody heavy 
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chain locus of chromosome 14 (Pegoraro et al., 1984). This (14;18) translocation 
places the BCL-2 gene close to the heavy chain gene enhancer, which is very 
active in B cells. As a result, BCL-2 protein is expressed at high levels in these 
cells, suppressing initiation of the apoptosis process (Williams 1991). 
 
Figure 5.15 
Immunohistological analysis of follicular lymphoma cases. Serial sections were prepared from 5 
samples of follicular lymphoma cases. The signals from P75NTR (clone C40-1457) and FDC 
marker (clone CNA42) were co-localized. 200x magnification of the same location had been 
investigated in order to observe any morphology that might be related to either FDC or other 
follicular component. In all of the five follicular lymphoma cases, similar observations were 
recorded. 50x magnification, scale bar: 200 µm on the left and 200x magnification, scale bar: 50 
µm on the right. Hemalaun was used for nuclear staining. 
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5.2. Animal study 
5.2.1 P75NTR expression in mouse spleen 
In wild type mice, strong expression of p75NTR was observed in the 
lymphoid follicles (Fig. 5.16) and the expression pattern in the mouse spleen and 
lymph nodes showed great resemblance to human tonsil/adenoids. 
As an initial step, before starting a detailed investigation of the immune 
phenotype of Ngfr exon 4 knockout mice (will be referred as KO or p75NTR KO), a 
series of immunohistological experiments were performed in order to confirm the 
complete deletion on protein level. As expected, anti-p75NTR antibody did not find 
any target in the spleen sections of p75NTR KO mouse  (Fig. 5.16). 
  Figure 5.16 
Cryosections from spleen of p75NTR KO and WT mice were probed with an anti-p75NTR antibody 
(ab8874) that targets the neurotrophin-binding domain of the receptor. In parallel, B220 
antibody (clone RA3-6B2) visualized B cells. WT spleen section showed a lymphoid follicle 
staining similar to the human adenoid/tonsils (upper panel), whereas KO sections lacked any 
signal from the anti-p75NTR antibody (lower panel). Absence of p75NTR did not affect formation of 
follicles. 
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5.2.2 Morphology and cellular composition of p75NTR KO mouse spleen 
A wide range of well defined markers that are associated with cellular or 
morphological compartments were used for comparison of WT and p75NTR KO 
mouse. A notable change in the morphology or the distribution of GC B cells and 
marginal zone B cells was similar in WT and KO mice. For the identification of 
different B cell subsets, IgM and IgD markers were used. Laminin antibody 
served for visualization of morphological structures (basic sinusoidal structure of 
the spleen, white and red pulp). Moma-1 and FDC-m1 antibodies were used for 
the identification of marginal zone macrophages and FDCs respectively. CD4 
and CD8 marked T cell areas, and finally FITC conjugated peanut agglutinin 
(PNA) was applied to locate germinal centres (Fig. 5.17) 
 
Figure 5.7 
Typical immunofluorescence staining of WT spleen in order to visualize cellular 
compartments. B220 (Red), CD4/8 (green) and laminin (blue) antibodies were used to 
visualize B and T cell areas and basement membrane components respectively (a), 
IgD (red), PNA (green) and IgM (blue) markers were included to see the distribution of 
different B cell subsets and germinal centres (b). Finally, using Moma-1 (red), it is 
possible to identify marginal zone macrophages and IgD+ B cells (blue). PNA (green) 
shows whether germinal centres exist or not (c). 
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Spleen sections taken from two sites of the spleen from p75NTR KO mouse 
showed similar morphology compared to WT (Fig. 5.18). Distribution of cellular 
compartments, the area and the shape of lymphoid follicles appeared to be 
normal in p75NTR KO mice.  
 
Figure 5.19   
Triple immunofluorescence staining of WT (right) and p75NTR KO (left) spleen sections 
were made using IgM (red), IgD (blue) and PNA (green) markers, in order to visualize 
distinct B cell compartments and germinal centres. There are no obvious morphological 
differences between p75NTR KO and WT spleens. The shape and size of lymphoid follicles 
are comparable; the organization of distinct cellular compartments seems not to be grossly 
affected by the deletion of p75NTR. 
. 
 
5.2.3 SRBC immunization of p75NTR KO mouse  
After the investigation of the WT and KO spleens under resting conditions, 
sheep red blood cell (SRBC) immunization was performed in order to induce a 
germinal centre response. Three time points were selected for analysis: 7, 14 
and 21 days. For each time point three WT and three KO mice were used. 
Similar to non-immunized animals, spleens of immunized ones did not show 
obvious morphological differences (Fig. 5.18). Germinal centre shapes and areas 
were compared and quantified. PNA was used as a GC marker in combination 
with anti-IgM and anti-IgD. 
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Figure 5.19   
Spleen cryosections from non-immunized and 7, 14, 21 day SRBC immunized WT and KO mice 
were stained with IgM, IgD and PNA markers to pinpoint germinal centres. Representative 
spleen sections of 7-day SRBC immunized animals are shown. Typically, a dense green PNA 
signal surrounded by a purple IgM staining shows a germinal centre (arrows). In the KO spleen 
(left), there are more germinal centres than in the spleen of the WT (right). 
 
For the quantification, sections from three distinct sites of the spleen were 
analysed for each mouse in a blind manner. In all of the three different time 
points after the immunization and in nonimmunized animals, p75NTR KO mice had 
more germinal centres per section, compared to wild type (Fig. 5.20). 
 
 
Figure 5.20   
Three WT and three p75NTR exon 4 KO mice were analysed for each time point. Three 
anatomically distant sections from each spleen were used for quantification of the GCs (nine 
sections were used for GC quantification per data point). KO animals have significantly more 
germinal centres per observed section compared to wild type on day 0,14 and 21 (error bars 
represent SEM, ∗: p<0,05 and ∗∗: p<0,01).  
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5.2.4 Cellular composition of p75NTR knockout mice 
In parallel with the experiments intended to compare the morphology of 
the spleen, a thorough analysis of splenocytes was performed to compare 
cellular distribution of the p75NTR KO mice compared to WT. A small portion of 
each spleen was used to isolate MNCs. 
 
Figure 5.21 
A total of three WT and thee KO mice were analysed for 
possible alterations in splenocyte compositions. There 
were no significant differences in T and B cell 
composition. Error bars represent standard deviation. 
 
Splenocytes were probed with a wide range of cell and state specific 
markers in combinations to allow quantitative comparison of different cell 
subsets. Differences that were observed between KO and WT animals (Fig. 5.21) 
were not statistically significant. All three B cell markers (B220, IgM, and IgD) 
showed the same pattern of expression throughout the immunization period (data 
not shown). 
 
5.2.5 Antibody production of p75NTR KO mice immunized with SRBC, VLP 
and OVA. 
Following the SRBC immunization that was performed to induce a strong 
GC response, further WT and KO mice were immunized with virus like particles 
(VLP) and ovalbumin (OVA). After SRBC immunization, blood sampling and 
serum preparation was done at day 7, 14 and 21. Total and antigen specific IgG 
and IgM levels were measured by ELISA (Fig. 5.22). 
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Figure 5.22 
Blood sampes were collected on at day 0, 7, 14 and 21 following the SRBC immunization. 
Serum samples (diluted 1:100 for IgM assay and 1:1000 for IgG assay) were analysed for 
total and SRBC specific IgG and IgM. There was no difference in total IgG and IgM levels, 
but SRBC specific IgM levels were higher in KO mice at day 7, 14 and 21 whereas SRBC 
specific IgG levels were different only on day 14 (o.d.: optical density, error bars 
represent standard deviation, n=3 for all groups, ∗: p<0,05 and ∗∗: p<0,01).  
 
There was no difference in total IgG and IgM amounts between WT and 
KO mice. When the amount of SRBC specific IgG and IgM were measured, KO 
mice had increased levels of SRBC specific IgM for all time points, and 
additionally SRBC specific IG on day 14 only. 
VLP immunization aimed to observe the memory function. Therefore 
primary Ig response was measured at day 7 and 14 after the initial immunization 
(Fig. 5.23). VLP specific IgM production was higher in p75NTR KO mice. There 
were no significant differences in VLP speific IgG levels. 
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Figure 5.23 
For quantifying primary VLP specific Ig production, blood was collected before 
immunization, as well as 7 and 14 days after immunization. Three KO and three WT mice 
were analysed for each time point, error bars stand for the standard deviation. The serum 
was diluted 1:100 for IgM and 1:1000 for IgG assays. VLP specific IgM production on day 7 
and 24 is higher in p75NTR KO mice whereas there was o diffrence in VLP specific IgG 
levels (n=3 for each group, ∗: p<0,05). 
 
For the quantification of the Ig response, a booster immunization was 
performed at day 60. Blood sampling was done before booster and 7 days after 
booster. First, serum samples were analysed for the total IgG and IgM content. 
No difference was observed between WT and KO (Fig. 5.24) after the initial and 
booster immunizations. Quantification of VLP specific Ig yielded a similar result to 
RBC immunization; VLP specific IgM titer was higher in KO mice during the 
primary and booster response while VLP specific IgG levels were similar (Fig. 
5.23 and 5.24). 
 
Figure 5.24 
Possible alterations in memory response due to the deletion of p75NTR were tested by a 
booster injection at day 60 followed by blood sampling at day 67. Total IgG and IgM 
production was found to be similar in KO and WT. VLP specific IgM production both before 
and after the booster immunization was significantly higher in KO mice compared to WT (n=3 
for all groups, ∗∗: p<0,01 and ∗∗∗: p<0.001, two tailed t-test, error bars stand for the standard 
deviation). The serum has been diluted 1:200 for IgM and 1:800 for IgG assays. 
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Finally, as a third antigen, OVA was injected to induce an immune 
response. Exactly the same time points for primary and booster immunizations 
were done as in VLP immunization. There was no difference between WT and 
KO in terms of total IgG and IgM both for primary (data not shown) and booster 
responses (Fig. 5.25). On the other hand, just like SRBC and VLP, OVA-specific 
IgM production was significantly higher in KO mice after initial (day 7) and 
booster injections (day 67) (Fig. 5.25). OVA specific IgG production was similar in 
WT and KO (data not shown). 
 
 
Figure 5.25 
OVA immunized mice were compared for primary Ig production; blood was collected 
before immunization and at day 7 and 14 after immunization. OVA specific IgM 
production was higher in p75NTR KO mice at day 7. Memory response was assessed 
by a booster injection at day 60 followed by blood sampling at day 67. OVA specific 
IgM production was significantly higher after booster at day 67 (n=3 for all groups, ∗: 
p<0,05, two tailed t-test). Serum dilution is 1:200 for day 0, 7 and 14, 1:400 for day 60 
and 67. 
 
Experiments performed with all three immunogens yielded parallel result in 
terms of antigen specific IgM production. Table 5.2 summarizes serum Ig 
quantification experiments performed by ELISA. Ig classes A and E were also 
tested and no difference has been observed between KO and WT (data not 
shown). 
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Table 5.2: Summary of the primary and secondary IgG and IgM response to 
the three applied antigens. 
 
 
Immunization!  
 
SRBC 
primary 
 
VLP  
primary 
 
VLP 
secondary 
 
OVA 
primary 
 
OVA 
secondary 
Total IgG KO = WT KO = WT KO = WT KO = WT KO = WT 
Total IgM KO = WT KO = WT KO = WT KO = WT KO = WT 
Antigen 
specific IgG 
KO > WT 
d14: p<0.05 
KO >= WT KO  = WT KO = WT KO = WT 
Antigen 
specific IgM 
 KO > WT 
 d7, 14: p<0.01 
 d21: p<0.05 
 KO > WT 
 d7, 14: p<0.05 
 
 KO > WT 
 d60: p<0.01 
 d67: p<0.001 
 KO > WT 
 d7: p<0.05 
 
 KO > WT 
 d67: p<0.05 
 
 
Table 5.2 
WT and KO mice were immunized with: Sheep red blood cells (SRBC), Ovalbumin (OVA) and 
virus like particles (VLP). Total and antigen specific IgG and IgM levels for primay response were 
measured 7, 14 and 21 days after first immunization. Secondary response was addressed 7 day 
following the secondary immunization done at day 60. Antigen specific IgM quantities were 
significantly higher in p75NTR knockout mice during both primary and secondary response against 
all three antigens used. Two tailed, paired student t-test was used for statistical analysis, n=3 for 
all groups. 
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6. Discussion 
 
The cells that form tissues need to properly communicate with each other for 
consistency of relevant functions. Although oligosaccharides, lipids, nucleotides or 
other small molecules act as signaling components, cell-to-cell signaling mainly relies 
on protein-protein interactions. In most cases, cells do communicate only with 
neighbouring cells depending on physical contact followed by interaction of surface 
receptors and membrane bound ligands (juxtacrine signaling). Additionally, cells may 
secrete factors that immediately act on themselves (autocrine signaling) or on distant 
cells (paracrine signaling). These soluble proteins have a wide range of roles from 
homeostasis to hormonal regulations. Neurotrophic factors and their receptors have 
many roles in this context. 
The strategy to investigate ligand receptor interaction is first to locate cells or 
tissues abundantly expressing those proteins and looking for immediate responses 
upon blockage or activation of signaling components. Accordingly, dated back to the 
initial period when the neurotrophins and neurotrophin receptors were newly 
identified, most of the studies were focussed to central and peripheral nervous 
system where these proteins have their main functions. Nevertheless, during 
following years, many studies have shown the expression of NGF family of 
neurotrophic factors and their receptors in other cells and organs, including several 
components of the immune system. This study is the first to systematically describe 
the dynamic expression of p75NTR on various human immune cell subsets. 
Ex vivo analysis of human peripheral blood lymphocytes revealed that CD56+ 
NK cells, CD8+ and CD4+ T cells express p75NTR and the expression level of both 
transcripts and proteins is induced upon activation. The increased level of p75NTR on 
human CD8+ T cells remained high up to 48 hours following activation, whereas the 
expression of CD4+ T cells went back to initial level (Data not shown). Since, T cells 
were previously reported to produce NGF (Ehrhard et al., 1993b; Santambrogio et al., 
1994; Lambiase et al., 1997) and BDNF (Besser and Wang, 1999, Kerschensteiner 
et al., 1999 and Berzi et al., 2008), it is worthwhile to consider autocrine or paracrine 
signaling in T cells through p75NTR, TRKA and TRKB. Herda et al. reported that CD4, 
CD8 T cells and NK cells express sortilin receptor and systemic deletion of sortilin 
resulted in a compromised immune response (Herda et al. 2012). It is possible that 
p75NTR-Sortilin receptor complex and proNGF/proBDNF mediated apoptosis play a 
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role in T cell functions. Thus, involvement of p75NTR signaling needs to be elaborated 
under this context. 
Following the increase in reports pointing out the presence of neurotrophin 
receptors and production of neurotrophic factors on different immune cell 
populations, scientist investigated inflammatory conditions involving the nervous 
system. Studies on EAE (experimental autoimmune encephalomyelitis) with Ngfr 
exon 4 knockout mice revealed a more severe disease course compared to WT mice 
(Copray et al., 2004). In parallel, an increased infiltration of T cells into the spinal cord 
has been reported (Küst et al., 2006). Concerning the T cell infiltration, a similar 
observation has been made during neuronal regeneration experiments involving 
peripheral transsection in a mouse model of facial nerve injury. In both Ngfr exon 3 
and exon 4 mutant mice models, absence of p75NTR led to an increased recruitment 
of CD3+ T lymphocytes in the axotomized facial motor nucleus (Gschwendtner et al., 
2003). In both EAE and facial nerve injury studies, researchers have not considered 
or discussed any possible outcomes of the absence of p75NTR expression in activated 
T cells and NK cells, which have the highest potential for infiltration upon injury or 
inflammation. 
It is clear that the ideal strategy to investigate the possible functions of a gene 
on an immune cell subset would rely on systems that allow selective deletion of that 
gene on a specific cell subset or lineage. To our knowledge, there is no study that 
has utilized conditional knockout mice, RNA silencing or inducible gene deletion 
systems to study functions of p75NTR in the immune system. This was a limitation for 
researchers but now there is a conditional p75NTR knockout line (Bogenmann, et al., 
2011), and it is also possible to engineer different experimental models by using 
CRISPR/Cas9 system (Huang et al., 2017). 
Apart from T cells and NK cells, the expression of p75NTR in peripheral blood B 
cells is an issue of concern since there are contradicting reports (Brodie et al., 1996, 
Schenone et al., 1996). In this study, less than 1% of peripheral blood B cells had 
p75NTR protein, just above the detection limit. On the other hand, a considerable 
expression of p75NTR was observed in magnetically isolated adenoid B cells. Further 
investigation of adenoid B cells that express p75NTR, revealed sub-populations 
bearing IgM, IgD, CD38 and CD27 but not CD77. These markers are differentially 
regulated in secondary lymphoid organs during arrival, selection, elimination, 
maturation and class-switch phases. Whether all of the B cells in the lymphoid 
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follicles express p75NTR during a certain phase of their selection/elimination process 
or the expression is only associated to specialized B cells remains unclear. 
The expression of p75NTR in the tonsil and adenoid was not confined only to B 
cells. When stained with additional surface markers, the presence of p75NTR on 
follicular dendritic cells was also confirmed. Follicular dendritic cells develop from 
putative mesenchymal precursors (Van Nierop et al., 2002), they attract and organise 
lymphoid cells by CXCL13 secretion (Vermi et al., 2008). Recently, p75NTR was 
established as a marker for human bone marrow mesenchymal stem cells (Álvarez-
Viejo et al., 2015). A prominent expression of p75NTR outside of the follicles was also 
observed along the basal layer of the squamous epithelium. Additionally, in spleen, 
p75NTR expression was distributed to lymph follicles, along central arterioles, splenic 
macrophages and endothelial lining at the border of white pulp. The follicular intensity 
of the immuno-staining shows variations from one follicle to another, probably due to 
the differences in the germinal centre reaction stage or the three dimensional 
localization of the section plane. 
These findings are in agreement with previous studies (Chesa et al., 1988, 
Brodie and Gelfand 1992, Pezzati et al., 1992) stating that p75NTR is primarily 
observed diffusely in the germinal centre cells, i.e. lymphocytes and FDCs (Burton et 
al., 1993, Hannestad et al., 1995, O. Garcia-Suarez et al., 1997, 1999 and Meada et 
al., 2002). Dendritic cells have also been reported to express p75NTR (Labouyrie et 
al., 1997, Bandola et al., 2017). 
As p75NTR signaling mainly relies on ligand binding, the next step was to 
identify a ligand in the tonsil/adenoids. Expression of BDNF but not NGF in lymph 
follicles has been confirmed on both protein and transcript level. Similar to p75NTR, 
BDNF protein was associated with both B cells and FDCs. Our collaboration partners 
Berzi et al., reported similar finding in hyperplastic thymus, additionally locating 
p75NTR on proliferating B cells. BDNF production in lymphoid follicles is of particular 
importance because Schuhmann et al. reported an impeded Pre-BII stage 
development in BDNF deficient mice (Schuhmann et al., 2005). In this context BDNF 
might be an important signaling molecule for B cell or FDC functions in germinal 
centres. Further analysis is required to determine which form of BDNF is expressed 
in the follicles, since our protein and transcript detection methods were not able to 
distinguish between BDNF and proBDNF. Since BDNF is a ligand for both p75NTR 
and TRKB, expression of TRKB receptor needed to be elucidated. 
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Immunohistochemical analysis showed that TRKB receptor was mainly expressed in 
the T cell area, in addition, marginal zone macrophages, FDCs and some 
lymphocytes, presumably B cells in follicles, were weakly positive as well. To be able 
to show the localised expression of p75NTR, TRKB and BDNF by quantitative PCR, 
laser microdissected lymphoid follicles and similar sized T-cell area were analysed. 
BDNF and p75NTR transcripts were more abundant in lymphoid follicles whereas TrkB 
was more prominent in the T cell area. It seems that TrkB is responsible for BDNF 
signaling outside of the follicles. Coexpression of p75NTR and BDNF in the follicles 
suggests a ligand dependent function through p75NTR. 
Apart from germinal centres in regular lymph follicles, extranodal follicles are 
found outside of immune organs during various chronic inflammatory conditions 
including autoimmune diseases, and follicular lymphomas in mucosa associated 
lymphoid tissue (MALT) or bronchus associated lymphoid tissue (BALT). In this 
study, extranodal follicles of autoimmune Hashimoto’s thyreoiditis and follicular B cell 
lymphoma were investigated for the expression of p75NTR on protein and transcript 
levels. Immunohistological analysis showed that p75NTR distribution in extranodal 
follicles is very similar to regular lymphoid follicles. Quantitative transcript analysis 
showed that in Hashimoto’s thyroiditis, p75NTR expression is significantly higher 
compared to healthy thyroid controls. We found similar results while assessing the 
presence of p75NTR in follicular B cell lymphomas. Monoclonal antibody clones C40-
1457 and ME 20.4 against human p75NTR provided robust FDC staining comparable 
with well-established markers CD21/1F8 and CNA.42, thus p75NTR could be used as 
a marker for healthy lymph follicles as well as autoimmune and malignant follicles. 
The expression of p75NTR on follicular dendritic cells might have therapeutical 
implications due to well-known apoptotic function through conserved death domain. 
Activation of cell-death signal by local delivery of recombinant ligands or mimicking 
molecules could be a used to eradicate malignant or autoimmune extranodal follicles.  
In order to assess in vivo functions of p75NTR in the immune system, further 
experiments were performed using p75NTR knockout mice. This study includes a 
detailed investigation of p75NTR exon 4 knockout mice for primary and secondary 
antibody response, memory function, germinal centre reaction and distribution of 
certain immune cell subsets. The strategy relies on the immunization of mice with 
three different antigens: Sheep red blood cells (SRBC), ovalbumin (OVA) and virus-
like particles (VLP) to observe the changes throughout the humoral immune 
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response. SRBC and OVA are T cell dependent antigens commonly used for 
studying antigen specific immune responses in mice. VLPs contain repetitive, high-
density displays of viral surface proteins that present conformational viral epitopes 
that can elicit strong T cell and B cell immune responses (Jegerlehner et al., 2002). 
As the main purpose of SRBC immunization was to induce a strong germinal 
centre response, we focused on histological analysis of the spleen by evaluation of 
cryosections stained with cardinal markers for relevant cell types. We did not find any 
remarkable morphological difference in germinal centre formations and distribution of 
cellular compartments. On the other hand, SRBC immunized p75NTR deficient 
animals had an increased number of germinal centres and increased total germinal 
centre area per analysed spleen section, compared to wild type mice. Considering 
well-established inhibitory role of p75NTR in the nervous system during axonal 
guidance by growth cone collapse or neuronal cell death, it is possible that lack of 
p75NTR in follicular dendritic cells or mesenchymal precursor cells might contribute to 
increased number of germinal centre formation. Following SRBC immunization, a 
gradual increase was observed in p75NTR mice for B220, IgM and IgD markers by 
flow cytometric analysis of splenocytes. Although the difference did not reach 
statistical significance compared to wild type mice, the raise in the number of 
germinal centres might be reflected to overall B cell counts. 
Analysis of serum for antibody production showed that p75NTR deficient mice 
have similar amount of total IgG and IgM. On the other hand, increased titers of 
antigen specific IgG and IgM were found compared to wild type mice. Interestingly, 
antigen specific IgM level were significantly higher for all time points, whereas 
antigen specific IgG level has reached significance at day 14 only. Immunization with 
OVA and VLP yielded similar results during primary response. Total IgG, total IgM 
and antigen specific IgG levels were similar while antigen specific IgM was elevated 
in p75NTR deficient mice compared to wild type. 
Elevated antigen specific IgM levels in p75NTR deficient mice following primary 
SRBC, OVA and VLP immunizations, suggest a role for p75NTR in B cell 
compartment. During the primary response, IgM is the first antibody produced by B 
cells upon exposure to antigen. The cells responsible for the initial production of 
antigen-specific IgM are splenic plasmablasts that are T-independent, and not found 
in germinal centres (Papillon et al., 2017). Later come the B cells that have 
undergone somatic hypermutation and selection but did not switch their isotype from 
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IgM to IgG or IgA. It is possible that p75NTR plays a role during elimination of less 
specific Ig-bearing centrocytes or later during class switching, in both case leading to 
elevated number of mature IgM+ cells and antigen specific IgM titer. 
To test the memory function, mice were challenged with VLP or OVA 60 days 
after primary immunization. Total and antigen specific serum IgG and IgM levels 
before and after booster injections were compared. In all cases, antigen specific IgM 
titer was higher in p75NTR deficient mice both before and after challenge. Existence of 
significantly elevated antigen specific IgM antibodies after challenge implies: 
1- Elevated antigen specific IgM after challenge might be due to the high IgM 
titer in p75NTR knockout mice before OVA or VLP challenge. It has been reported that 
administration of antigen specific IgM antibody together with antigen can highly 
enhance the immune response; this has been shown by immunizing mice with SRBC 
and anti-SRBC IgM antibodies (Heyman et al., 1982). 
2- The possibility of increased number of IgM memory cells or long living IgM 
plasma cells that have been generated after primary immunization. It is well known 
that these cells can persist for longer periods maintained in distinct immunological 
niches, in the absence of immunizing antigen (Maruyama et al., 2000) or supporting 
cytokines like BAFF (B-cell activating factor) and APRIL (A Proliferation-Inducing 
Ligand) (Benson et al., 2008). Within these niches, absence of p75NTR may lead to 
selective activation of Trk receptors on memory B cells, long living plasma cells, 
supporting epithelial and stromal cells. Concomitant phosphorylation of thyrosine 
kinases of Trk receptors initiate RAS and MAP kinase pathways, which in turn 
activate transcription factors promoting maintenance and survival. 
3- IgM memory cells reside in the spleen and reinitiate a germinal centre 
response after challenge (Dogan et al., 2009). IgM memory cells are also present in 
patients lacking germinal centres, but in reduced numbers, demonstrating partial T 
cell and germinal centre dependence (Tangye SG et al., 2007, 2009), implicating that 
more germinal centres yield more IgM memory cells. 
 Altogether, this is the first study showing that human peripheral blood T cells 
and NK cells express p75NTR, rendering them responsive to NGF family of 
neurotrophins and proneurotrophins. On the other hand peripheral blood B cells were 
negative for p75NTR. The effects of different neurotrophins on lymphocytes were 
reported and it is well known that NGF expression is elevated under inflammatory 
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conditions and lymphocytes are able to secrete NGF and BDNF as well, implicating 
both paracrine and autocrine signaling in the vicinity. 
As for human secondary lymphoid organs, p75NTR was detected in B cells and 
follicular dendritic cells.  Although it was not possible to link p75NTR expression to a 
single B cell subset with our settings, we detected a gradual expression associated to 
centrocyte selection and memory B cell maturation, whereas arriving centroblasts 
and mature plasma cells were negative for p75NTR. Strong immunoreactivity of 
p75NTR and BDNF in germinal centres that is associated to both follicular dendritic 
cells and B cells and more prominent TrkB expression in T cell area, left p75NTR as 
the primary receptor for neurotrophins signaling within germinal centres. 
In vivo experiments that were performed show that the immune system of the 
p75NTR deficient mice is fully capable and shows no significant sign of loss of 
function. Comparable total IgM, total IgG and antigen specific IgG levels upon 
independent immunizations with three different antigens, indicate that p75NTR 
signaling has no crucial function in adaptive immune response. Elevated number of 
germinal centres and antigen specific IgM concentrations indicate for a possible 
regulation through p75NTR. 
There is an increasing body of data suggesting that neurotrophins and 
neurotrophin receptors have key roles in the immune system. They are expressed in 
the close vicinity of inflammation and immune organs with a potential to trigger 
molecular mechanisms. It is worthwhile investigating neurotrophin signaling to better 
understand their role during inflammatory conditions. 
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8. Appendices 
 
8.1 Abbreviations 
AA Amino acid 
APC Antigen presenting cell 
APC Allophycocyanin 
BALT Bronchus associated lymphoid tissue 
BBB Blood brain barrier 
BDNF Brain derived neurotrophic factor 
BEM Both ear marking 
BMSC Bone marrow stromal cell 
CD Cluster of differentiation 
cDNA Complimentary DNA 
CFA Complete Freund’s adjuvant 
CMV Cytomegalovirus 
CNS Central nervous system 
CRD Cysteine rich domain 
CRR Cysteine rich region 
CT Cycle treshold 
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 
DAPI 4',6-diamidino-2-phenylindole 
DD Death domain 
DRG Dorsal root ganglia 
EAE Experimental autoimmune encephalomyelitis 
ECD Extracellular domain 
EGF Epidermel growth factor 
ER Endoplasmic reticulum 
ESC Embryonic stem cell 
FACS Fluorescence activated cell sorting 
FCS Fetal calf serum 
FDC Follicular dendritic cells 
FFPE Formalin fixed paraffin embedded 
FITC Fluorescein isothiocyanate 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
Gb Glycoprotein B 
GC Germinal centre 
GM-CSF Granulocyte macrophage colony stimulating factor 
GOI Gene of interest 
HCMV Human cytomegalovirus 
HFF Human foreskin fibroblasts 
HSC Hemopoietic stem cell 
HT Hashimoto’s Thyroiditis 
i.p. Intraperitoneal 
i.v. Intravenous 
ICD Intracellular domain 
IFA Incomplete Freund's adjuvant 
IFNγ Interferon gamma 
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Ig Immunoglobulin 
IFNβ Interferon beta  
IP3 Inositol tri-phosphate 
IRAK Interleukin 1 receptor associated kinase 
JMD Juxta-membrane domain 
KO Knock-out 
LANGFR Low affinity nerve growth factor receptor 
LANR Low affinity neurotrophin receptor 
LCM Laser capture microdissection 
LEM   Left ear marking 
LLPC Long living plasma cell 
LPS Lipopolysaccharide 
LRR Leucine rich regions 
LTP Long term potentiation  
mAbs Monoclonal antibodies 
MAG Myelin associated glycoprotein 
MALT Mucosa associated lymphoid tissue 
MDGI Myelin derived growth inhibitors 
MMP Matrix metalloprotease 
MNCs Mononuclear cells  
MOG Myelin oligodendrocyte glycoprotein 
MS Multiple sclerosis 
NADE Neurotrophin associated death executor 
NGF Nerve growth factor  
NGFR Nerve growth factor receptor 
NGR Nogo receptor 
NK Natural Killer  
NRAGE Neurotrophin receptor-interacting MAGE homologue 
NRIF Neurotrophin receptor interacting factor 
NT Neurotrophin 
NTBD Neurotrophin binding domain 
NTR Neurotrophin receptor 
NTRK Neurotropic tropomyosin receptor kinase 
OMgp Oligodendrocyte myelin glycoprotein 
OVA Ovalbumin 
PAP Peroxidase anti-peroxidase 
PBMCs Peripheral blood mononuclear cells 
PB Peripheral blood 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PE Phycoerythrin 
PerCP Peridinin chlorophyll protein 
PFA Paraformaldehyde  
PI3-kinase Phosphodityl-insitol 3-kinase 
PKC Protein kinases C  
PLC-γ Phospholipase C-gamma 
PNA Peanut agglutinin 
PNS Peripheral nervous system 
PPIA Peptidyl-prolyl isomerase A, Cyclophilin A 
ProNT Pro-neurotrophin 
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PWM Pokeweed mitogen 
qPCR Quantitative PCR 
RA Rheumatoid arthritis 
RBCs Red blood cells 
RG Reference gene 
REM Right ear marking 
RT Reverse Transcription 
s.c. Sub-cutaneous 
sABC Streptavidin-avidin biocomplex 
SAC Staphylococcus Aurous Cowan 1 
SD Stalk domain  
Sd Standard deviation 
SEM Standard error of the mean 
S-p75 p75 short isoform 
SRBCs Sheep red blood cells 
TACE TNFα converting enzyme 
TAE Tris-Acetate-EDTA 
TBS Tris buffered saline 
TCR T cell receptor 
TEC Thymic epithelial cells 
TGFβ Tumor growth factor beta 
TLR Toll-like receptor 
TMB Tetra-methyl-benzidine 
TMD Transmembrane domain 
TNFα Tumor necrosis factor alpha 
TNFR Tumor necrosis factor receptor 
TNFRSF Tumor necrosis factor receptor superfamily 
TRAF6 TNF recetor assocated factor 6 
Trk The protein tyrosine kinase 
VCAM-1 Vascular cell adhesion molecule1 
VLP Virus like particles 
WT Wild type 
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